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biases and artifacts. We propose CODEX, a normalization and CNV calling procedure for WES data.
CODEX includes a Poisson latent factor model, which includes terms that specifically remove biases due to
GC content, exon capture and amplification efficiency, and latent systemic artifacts. CODEX also includes a
Poisson likelihood-based segmentation procedure that explicitly models the count-based WES data. CODEX
is compared to existing methods on germline CNV detection in HapMap samples using microarray-based
gold standard and is further evaluated on 222 neuroblastoma samples with matched normal, with focus on
somatic CNVs within the ATRX gene.
Part 2: Cancer is a disease driven by evolutionary selection on somatic genetic and epigenetic alterations. We
propose Canopy, a method for inferring the evolutionary phylogeny of a tumor using both somatic copy
number alterations and single nucleotide alterations from one or more samples derived from a single patient.
Canopy is applied to bulk sequencing datasets of both longitudinal and spatial experimental designs and to a
transplantable metastasis model derived from human cancer cell line MDA-MB-231. Canopy successfully
identifies cell populations and infers phylogenies that are in concordance with existing knowledge and ground
truth. Through simulations, we explore the effects of key parameters on deconvolution accuracy, and compare
against existing methods.
Part 3: Allele-specific expression is traditionally studied by bulk RNA sequencing, which measures average
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bursting. We propose SCALE to analyze genome-wide allele-specific bursting, with adjustment of technical
variability. SCALE detects genes exhibiting allelic differences in bursting parameters, and genes whose alleles
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globally, cis control in gene expression overwhelmingly manifests as differences in burst frequency.
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ABSTRACT 
 
STATISTICAL METHODS FOR GENOMIC AND TRANSCRIPTOMIC SEQUENCING 
Yuchao Jiang 
Nancy R. Zhang 
Part 1: High-throughput sequencing of DNA coding regions has become a common way of 
assaying genomic variation in the study of human diseases. Copy number variation (CNV) is an 
important type of genomic variation, but CNV profiling from whole-exome sequencing (WES) is 
challenging due to the high level of biases and artifacts. We propose CODEX, a normalization 
and CNV calling procedure for WES data. CODEX includes a Poisson latent factor model, which 
includes terms that specifically remove biases due to GC content, exon capture and amplification 
efficiency, and latent systemic artifacts. CODEX also includes a Poisson likelihood-based 
segmentation procedure that explicitly models the count-based WES data. CODEX is compared 
to existing methods on germline CNV detection in HapMap samples using microarray-based gold 
standard and is further evaluated on 222 neuroblastoma samples with matched normal, with 
focus on somatic CNVs within the ATRX gene. 
Part 2: Cancer is a disease driven by evolutionary selection on somatic genetic and epigenetic 
alterations. We propose Canopy, a method for inferring the evolutionary phylogeny of a tumor 
using both somatic copy number alterations and single nucleotide alterations from one or more 
samples derived from a single patient. Canopy is applied to bulk sequencing datasets of both 
longitudinal and spatial experimental designs and to a transplantable metastasis model derived 
from human cancer cell line MDA-MB-231. Canopy successfully identifies cell populations and 
infers phylogenies that are in concordance with existing knowledge and ground truth. Through 
simulations, we explore the effects of key parameters on deconvolution accuracy, and compare 
against existing methods. 
Part 3: Allele-specific expression is traditionally studied by bulk RNA sequencing, which 
measures average expression across cells. Single-cell RNA sequencing (scRNA-seq) allows the 
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comparison of expression distribution between the two alleles of a diploid organism and thus the 
characterization of allele-specific bursting. We propose SCALE to analyze genome-wide allele-
specific bursting, with adjustment of technical variability. SCALE detects genes exhibiting allelic 
differences in bursting parameters, and genes whose alleles burst non-independently. We apply 
SCALE to mouse blastocyst and human fibroblast cells and find that, globally, cis control in gene 
expression overwhelmingly manifests as differences in burst frequency. 
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CHAPTER 1  
NORMALIZATION AND COPY NUMBER VARIATION DETECTION BY WHOLE EXOME 
SEQUENCING 
1.1 Introduction 
Copy number variants (CNVs) are large insertions and deletions that lead to gains and losses of 
segments of chromosomes. CNVs are an important and abundant source of variation in the 
human genome (1-4). Like other types of genetic variation, some CNVs have been associated 
with diseases, such as neuroblastoma (5), autism (6), and Crohn’s disease (7). Better 
understanding of the genetics of CNV-associated diseases requires accurate CNV detection. 
Traditional genome-wide approaches to detect CNVs make use of array comparative genome 
hybridization (CGH) or single nucleotide polymorphism (SNP) array data (8-10). The minimum 
detectable size and breakpoint resolution, which are correlated with the density of probes on the 
array, are limited. Paired end Sanger sequencing, which is often used as the gold standard 
platform for CNV detection, has better resolution and accuracy but requires significant time and 
budget investment. 
With the dramatic growth of sequencing capacity and the accompanying drop in cost, 
massively parallel next-generation sequencing (NGS) offers appealing platforms for CNV 
detection. Many current analysis methods are focused on whole genome sequencing (WGS), 
which allows for genome-wide CNV detection and finer breakpoint resolution than array-based 
approaches (11-15). Whole exome sequencing (WES), on the other hand, has been preferred as 
a cheaper, faster, but still effective alternative to WGS in large-scale studies, where the priority 
has been to identify disease associated variants in coding regions (16-19). 
Due to the biases and artifacts introduced during the exon targeting and amplification 
steps of WES, depth of coverage in WES data is heavily contaminated with experimental noise 
and thus does not accurately reflect the true copy number.  Here we present a novel 
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normalization and CNV calling method, CODEX (COpy number variation Detection by EXome 
sequencing) (20), to remove biases and artifacts in WES data and produce accurate CNV calls. 
Several algorithms have been developed for copy number estimation with whole exome 
data in matched case/control settings by either directly using the matched normal (21-23) or 
building an optimized reference set (24, 25) to control for artifacts. Other algorithms use singular 
value decomposition (SVD) to extract copy number signals from noisy coverage matrices by 
removing 𝐾 latent factors that explain the most variance (26-28). This exploratory approach 
assumes continuous measurements with Gaussian noise, uses an arbitrary choice of 𝐾, and 
doesn’t specifically model known quantifiable biases, such as those due to GC content. 
CODEX does not require matched normal controls, but relies on the availability of 
multiple samples processed using the same sequencing pipeline. Unlike current approaches, 
CODEX uses a Poisson log-linear model that is more suitable for discrete count data. The 
normalization model in CODEX includes terms that specifically remove biases due to GC content, 
exon length and capture and amplification efficiency, and latent systematic artifacts. We explore 
several different statistical approaches for choosing the number of latent factors, and discuss how 
one should set this crucial parameter wisely. The power of CODEX and SVD-based approaches 
are compared by in silico spike-in studies on the 1000 Genomes Project (29) WES data and show 
that CODEX offers higher power in detecting both common and rare CNVs. Also, on WES data 
from the 1000 Genomes Project paired with SNP array data from three previous cohort studies on 
the same HapMap samples (30-32), CODEX gives higher precision and recall for both rare and 
common CNV detection by WES data, as compared to existing methods. CODEX's normalization 
and segmentation accuracy is further evaluated through the analysis of the WES data of 222 
neuroblastoma matched tumor/blood samples from the TARGET project (33), with a focus on the 
well-studied ATRX gene region (33-35). The cross-sample normalization procedure of CODEX, 
when applied to the matrix of tumor samples, is more effective in reducing noise than normalizing 
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each tumor to its matched normal. The somatic deletions in the ATRX region have a nested 
structure, which CODEX was able to recover. 
1.2 Results 
1.2.1 Overview of Analysis Pipeline 
Figure 1.1 shows an overview of the analysis pipeline of CODEX. We start with mapped reads 
from BAM files (36) that are assembled, sorted, and indexed by the same pipeline, and compute 
depth of coverage after a series of quality filtering based on mappability, exon size, and a cutoff 
on minimum coverage (see details below). Then, we fit a normalization model based on a log-
linear decomposition of the depth of coverage matrix into effects due to GC content, exon capture 
and amplification, and other latent systemic factors. The normalization model produces an 
estimated “control coverage” for each exon and each sample, which is the coverage we expect to 
see if there is no CNV. Next, the observed coverage for each exon and each sample is compared 
to the corresponding estimated control coverage in a Poisson likelihood-based segmentation 
algorithm, which returns a segmentation of the genome into regions of homogeneous copy 
number. A direct estimate of the relative copy number, in terms of fold change from the expected 
control value, can be used for genotyping. CODEX is freely available as a Bioconductor R 
package at http://bioconductor.org/packages/CODEX/. 
1.2.2 Read Depth Normalization 
Due to the extremely high level of systemic bias in WES data, normalization is crucial in WES 
CNV calling.  CODEX's multi-sample normalization model takes as input the WES depth of 
coverage, exon-wise GC content, and sample-wise total number of reads. Specifically, we denote 
𝑌 as the coverage matrix with row 𝑖 (1 ≤ 𝑖 ≤ 𝑛) corresponding to the thi  exon and column 𝑗 (1 ≤
𝑗 ≤ 𝑚) to the 𝑗th sample, 𝐺𝐶𝑖 as the GC content for exon 𝑖, and 𝑁𝑗 as the total number of mapped 
reads for sample 𝑗. The “null” model, which reflects the expected coverage when there is no 
CNVs, is 
𝑌𝑖𝑗  ~ Poisson(𝜆𝑖𝑗) 
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𝜆𝑖𝑗 = 𝑁𝑗𝑓𝑗(𝐺𝐶𝑖)𝛽𝑖 exp (∑ 𝑔𝑖𝑘ℎ𝑗𝑘
𝐾
𝑘=1
), 
 where 𝑓𝑗(𝐺𝐶𝑖) is the bias due to GC content for exon 𝑖 sample 𝑗; 𝛽𝑖 reflects the exon-specific bias 
due to length and capture and amplification efficiency of exon 𝑖; and 𝑔𝑖𝑘ℎ𝑗𝑘  (1 ≤ 𝑘 ≤ 𝐾) are the 
thk  latent Poisson factors for exon 𝑖 and sample 𝑗. The goal of fitting the null model to the data 
is to estimate the various sources of biases, which can then be used for normalization. 
We adopt a robust iterative maximum-likelihood algorithm for estimating the parameters 
of the null model. Briefly, in each iteration, we estimate 𝑓(𝐺𝐶) by fitting a smoothing spline of 
𝑌 𝑁𝛽exp (𝑔 × ℎ𝑇)⁄  against the GC content, using the built-in function smooth.spline in R. 𝛽 takes 
the value of the median of each row in 𝑌 𝑁𝑓(𝐺𝐶)exp (𝑔 × ℎ𝑇)⁄ . The latent variables 𝑔𝑖𝑘ℎ𝑗𝑘  (1 ≤
𝑘 ≤ 𝐾) are estimated in the following steps: (i) take known ℎ as covariates, fit 𝑛 Poisson log-linear 
regressions with each row of 𝑌 as the response and corresponding row of log (𝑁𝑓(𝐺𝐶)𝛽) as the 
fixed offset; (ii) take known 𝑔 as covariates, fit 𝑚 Poisson log-linear regressions with each column 
of 𝑌 as the response and corresponding column of log (𝑁𝑓(𝐺𝐶)𝛽)  as the fixed offset; (iii) apply 
SVD to the row-centered matrix 𝑔 × ℎ𝑇 to obtain the 𝐾 right singular vectors to update ℎ. The third 
step ensures the uniqueness and orthogonality of the updated components, which forces the 
identifiability of 𝑔𝑖𝑘ℎ𝑗𝑘  (1 ≤ 𝑘 ≤ 𝐾) (37). We fit the Poisson log-linear models with the built-in 
function glm in R. See below for details of the maximum-likelihood algorithm. Procedures for 
determining 𝐾, the number of latent Poisson factors, is discussed later in 1.4.3 Poisson Latent 
Factors and Choice of K. 
Initialization 
𝛽𝑜𝑙𝑑 = 1𝑛 , 𝑔 = 0𝑛×𝐾 , ℎ = 0𝑚×𝐾. 
Iteration 
i. For each sample 𝑗, fit a smoothing spline of [𝑌 𝑁𝑗𝛽
𝑜𝑙𝑑exp (𝑔 × ℎ𝑇)⁄ ]
:𝑗
 to get 𝑓𝑗(𝐺𝐶). 
ii. For each exon 𝑖, update 𝛽𝑖 as 𝛽𝑖
𝑛𝑒𝑤 = median([𝑌 𝑁𝑓(𝐺𝐶)exp (𝑔 × ℎ𝑇)⁄ ]𝑖:). 
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iii. Denote 𝑍 = 𝑁𝑓(𝐺𝐶)𝛽𝑛𝑒𝑤. Apply SVD to row-centered log (𝑌 𝑍⁄ ) to obtain the 𝐾 right 
singular vectors and use as ℎ𝑜𝑙𝑑 . 
a. Fit n  Poisson log-linear regressions with 𝑌𝑖: as response, ℎ
𝑜𝑙𝑑 as covariates, log (𝑍𝑖:) 
as fixed offset to obtain updated estimates as 𝑔. 
b. Fit 𝑚 Poisson log-linear regressions with 𝑌:𝑗 as response, 𝑔 as covariates, log (𝑍:𝑗) as 
fixed offset to obtain updated estimates as ℎ𝑛𝑒𝑤. 
c. Center each row of 𝑔 × (ℎ𝑛𝑒𝑤)𝑇 and apply SVD to the row-centered matrix to obtain 
the 𝐾 right singular vectors to update ℎ𝑛𝑒𝑤. 
d. Repeat steps a to c with ℎ𝑜𝑙𝑑 = ℎ𝑛𝑒𝑤  until convergence to obtain ℎ and 𝑔. 
iv. Repeat steps i to iii with 𝛽𝑜𝑙𝑑 = 𝛽𝑛𝑒𝑤  until convergence. 
After the normalization procedure, we obtain ?̂? = 𝑁?̂?𝑓(𝐺𝐶) exp(?̂? × ℎ̂𝑇), which is the 
expected “control coverage” in the event where there is no CNV. As described later, the observed 
coverage 𝑌 will be compared to the corresponding estimated control coverage ?̂? to test for the 
presence of CNVs. 
For CNV detection under case-control settings (e.g. tumor with normal) involving 
recurrent large chromosomal aberrations, CODEX estimates the exon-wise Poisson latent factor 
{𝑔𝑖𝑘} using only the read depths in the control cohort, and then computes the terms {ℎ𝑗𝑘} for the 
case samples by regression. This leads to higher sensitivity for detecting variants that are present 
only in the case samples. CODEX also includes two modes—“integer” mode that returns copy 
numbers as integers for germline CNV detection and “fraction” mode that returns fractional copy 
numbers for CNV detection of samples with heterogeneous genetic compositions. 
1.2.3 CNV Detection and Copy Number Estimation 
Proper normalization sets the stage for accurate segmentation and CNV calling.  For germline 
CNV detection in normal samples, many CNVs are short and extend over only one or two exons.  
In this case, simple gene- or exon-level thresholding is sufficient. 
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For longer CNVs and for copy number estimation in tumors where the events are 
expected to be large and exhibit nested structure, we propose a Poisson likelihood-based 
recursive segmentation algorithm. Let 𝑦𝑠, … , 𝑦𝑡 and 𝜆𝑠, … , 𝜆𝑡 be the raw and estimated control 
coverage of the window spanning exon 𝑠 to exon 𝑡. The values 𝜆𝑠, … , 𝜆𝑡 are estimated by the 
normalization procedure described in the previous section, but suppressing the sample indicator 𝑗 
since we segment each sample separately.  A joint cross-sample segmentation, as proposed in 
Zhang et al. (38), can also be applied and may yield more accurate results for detection of 
germline CNVs.  Let 𝑦𝑠:𝑡 = ∑ 𝑦𝑖
𝑡
𝑖=𝑠  and 𝜆𝑠:𝑡 = ∑ 𝜆𝑖
𝑡
𝑖=𝑠 . The scan statistic we use is max𝑠,𝑡𝑈(𝑠, 𝑡), 
where 
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The above is the generalized log-likelihood ratio of the alternative model, 𝑦𝑠:𝑡  ~ Poisson(𝜇) with 𝜇 
arbitrary, versus the null model, 𝑦𝑠:𝑡  ~ Poisson(𝜆𝑠:𝑡). The copy number estimate for the window is 
given by 2𝑦𝑠:𝑡  𝜆𝑠:𝑡⁄ . 
 Given the scan statistic, CODEX performs a circular binary segmentation procedure (39) 
using 𝑈(𝑠, 𝑡). We further use a modified Bayes Information Criterion (mBIC) to determine the 
number of change points 𝑃 in our model (40), 
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where the first term is the generalized log-likelihood ratio for the model with 𝑃 change points 
versus the null model with no change points; 𝜏𝜌 (1 ≤ 𝜌 ≤ 𝑃) is the 𝜌th change point, 1 = 𝜏0 <
𝜏1 < ⋯ < 𝜏𝑃 < 𝜏𝑃+1 = 𝑛; 𝑛 is the number of exons. We report the segmentation with ?̂? =
𝑎𝑟𝑔𝑚𝑎𝑥𝑃𝑚𝐵𝐼𝐶(𝑃). Compared with algorithms based on HMM such as XHMM (28) and 
EXCAVATOR (25), CODEX doesn't require the user to pre-specify unknown parameters, such as 
expected distance between exons, exon-wise CNV rate, and average number of exons in a CNV. 
These quantities are often hard to set a priori without a large relevant training data set, and in 
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many cases have to be chosen arbitrarily. Post-segmentation, CODEX outputs an estimate of the 
relative copy number in terms of fold change from the expected control coverage, rather than a 
binary categorization of deletion and duplication as in CoNIFER (26) and XHMM (28). 
1.2.4 Calling Germline Variations from HapMap Samples 
To examine the accuracy of CODEX and to illustrate its application, we use a publicly available 
WES data set from the 1000 Genomes Project Phase 1 release (29) containing 90 healthy 
individuals. 46 samples are sequenced at the Washington University Genome Sequencing Center 
(captured by HSGC VCRome) and 44 at the Baylor College of Medicine (captured by SureSelect 
All Exon V2). All samples have Omni and Axiom genotypes and have more than 70% of exome 
targets covered to 20x or more. Sex is well balanced (44 males and 46 females) and population 
(40 Utah residents with northern and western European ancestry (CEU), 24 Japanese people 
from Tokyo (JPT), and 26 Yoruba people from Ibadan (YRI)) adds a potential source of latent 
variation. 
Effectiveness of normalization procedure 
We first examine the effectiveness of CODEX’s proposed normalization model on the 1000 
Genomes Project WES data set (29). Previous studies have shown that read depth has a 
unimodal relationship with GC content—regions with high or low GC content tend to have 
decreased read depth (41). In our smoothed estimates of 𝑓𝑗(𝐺𝐶), we find that most but not all 
samples have a unimodal shape for this function. We show the predicted values of 𝑓𝑗(𝐺𝐶) for 4 
typical samples in Figure 1.2. Interestingly, we found that some samples have estimates with 
multiple peaks in 𝑓𝑗(𝐺𝐶), which suggests that a parametric functional form assuming unimodality 
may be too simplistic. Comparing across samples, we see that the function 𝑓𝑗(𝐺𝐶) changes in 
shape and not just by a scaling factor. Therefore, the GC content bias is not linear across 
samples and thus cannot be fully captured by linear latent factor models.  This motivates the 
separate nonparametric term in our model for GC bias. 
 
8 
 
We further compare the normalization result of CODEX against that of SVD based 
method using array-based CNV calls from the International HapMap Consortium (30) on the 
same samples we analyze. For different categories of CNV events, namely, homozygous 
deletions, heterozygous deletions, and duplications, we use direct thresholding of log (𝑌 ?̂?⁄ ) to 
draw receiver operating characteristic (ROC) curves of our model, where ?̂? is the estimated 
control coverage from CODEX’s normalization procedure. The ROC curves for SVD-based 
normalization are drawn by thresholding on the residuals obtained by subtracting the first 𝐾 PCs 
from the original read depth 𝑌. Analysis is carried out for each of the following category of events 
separately: common homozygous deletion, common heterozygous deletion, common duplication, 
rare heterozygous deletion, and rare duplication (Figure 1.3). There are no rare homozygous 
deletions as all of the rare deletions from the HapMap CNV call set are present in only 
heterozygous form. We see that CODEX’s normalization procedure leads to a better signal-to-
noise ratio for both common and rare CNVs, and for both deletions and duplications (Figure 1.3). 
Accuracy of CNV calling 
We next compare the accuracy of CODEX to existing approaches that are designed for 
population-based CNV calling.  These programs include CoNIFER (26), XHMM (28), and 
EXCAVATOR (25) in its “pooling” mode, for which we added four additional samples as controls. 
The number of calls made by each program on each chromosome sample, broken down 
into common and rare calls, is shown in Table 1.1. Globally, CODEX detects twice as many CNV 
events as XHMM does and nearly 10 times as many as CoNIFER does, while EXCAVATOR and 
CODEX have comparable number of calls. CoNIFER detects the fewest CNVs in total, which 
agrees with comparisons against EXCAVATOR made in Magi et al. (25). Since CoNIFER does 
not automatically choose the number of PCs, we fix the number of PCs filtered out by CoNIFER 
at 4, agreeing with the selection made by XHMM so as to make the two SVD-based programs 
comparable. The choice of 4 PCs in normalization should not account for the low number of calls 
made by CoNIFER, since through the scree plot output by CoNIFER, we find the curve of relative 
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contributed variance to be still significantly decreasing at 4, indicating that the choice of 4 is 
conservative. A large proportion of XHMM and CoNIFER calls are rare (<5%) variants—52.46% 
(501/955) and 83.07% (157/189) respectively.  Despite the bias in sensitivity of XHMM and 
CoNIFER towards rare variants, CODEX detects even more rare CNVs in total as well as 
proportionately more common ones. Notably, the number of latent factors K selected by CODEX 
is for most chromosomes one less than the number of PCs excluded by XHMM across the 
genome. Furthermore, CODEX and XHMM tends to detect shorter CNVs compared to CoNIFER 
and EXCAVATOR in units of both kb (Figure 1.4a) and exon (Figure 1.4b). 
 We assess the CNV calls made by the four methods by comparing to calls reported by 
the International HapMap Consortium (30), McCarroll et al. (31), and Conrad et al. (32) in the 
same 90 HapMap samples. The International HapMap 3 Consortium produced a clean CNV call 
set by merging and utilizing probe-level intensity from both Affymetrix and Illumina arrays, 
containing 856 copy number polymorphisms (CNPs) with a 99.0% mean call rate and 0.3% 
Mendelian inconsistency (30). Separately, McCarroll et al. developed a map consisting of 1320 
CNVs at 2-kb breakpoint resolution by joint analysis of Affymetrix SNP array, array CGH (42) and 
fosmid end-sequence-pair data (31, 43). The third source of validation we use is the call set from 
Conrad et al., who used Nimblegen tiling oligonucleotide arrays to generate a map of 11,700 
CNVs greater than 443 base pairs, of which 8,599 have been validated independently (32). The 
genotyped CNPs from these three cohort studies that overlap with exon regions (73, 123, and 
377 in total respectively) are used as “validation set” to assess sensitivity and specificity of the 
four methods compared in Table 1.1. Figure 1.5 shows the precision and recall rates (precision is 
the proportion of calls made by the program that overlap with validation set, and recall is the 
proportion of the CNVs in validation set that are called.)  The different programs vary 
considerably in precision and recall rate.  CODEX has the highest F-measure (harmonic mean of 
precision and recall) for both common and rare CNVs. XHMM performs well in detecting rare 
variants but is insensitive to common ones. CoNIFER has the highest precision when comparing 
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against calls from the International HapMap Consortium (Figure 1.5a) and McCarroll et al. (Figure 
1.5c) but gives poor results against Conrad et al. (Figure 1.5b). Furthermore, the high precision of 
CoNIFER come with significant sacrifice on recall. See Table 1.2 for detailed comparison results 
based on the three SNP array metrics. 
1.2.5 Sensitivity Assessment with Spike-in Study 
We next conduct an in silico spike-in study to assess the sensitivity of the different methods at 
varying population frequencies. Starting with the WES data from chromosome 20 of the 𝑚 = 90 
HapMap samples analysed in the previous Section, we spike CNV signals in to copy-number-
neutral regions. We define a region to be copy-number-neutral if it doesn’t overlap with CNV calls 
made by CODEX, XHMM, EXCAVATOR, and CoNIFER nor with previously reported CNV 
regions by DGV (http://dgv.tcag.ca/dgv/app/) and dbVar (http://www.ncbi.nlm.nih.gov/dbvar/). Of 
the 3966 exon targets on chromosome 20, 1035 pass this criterion for copy-number-neutral. We 
consider only heterozygous deletions of two different lengths (5 and 10 exons) and varying 
population frequencies 𝑝 ∈ {5%, 10%, … ,95%}.  We focus on heterozygous deletions because (i) 
homozygous deletions are easily detectable by all methods; (ii) heterozygous deletions with 
frequency 𝑝 in the population have exactly the same detection accuracy as duplications with 
frequency 1 − 𝑝.
 
Specifically, for deletions with population frequencies greater than 50%, copy-
number-neutral states are reported as duplications whereas deletions are reported as normal 
events, since all copy number events are defined in reference to a population average. Events 
are centered at every hundredth exon and 𝑚 × 𝑝 samples are randomly chosen to be carriers. To 
generate CNV signals for heterozygous deletions, we reduce the raw depth of coverage for exons 
spanned by the CNV from 𝑦 to 
𝑐
2
× 𝑦, where 𝑐 is sampled from a normal distribution with mean 1 
and standard deviation 0.1. 
 We apply CODEX to these spike-in data sets and compare it to SVD-based normalization 
followed by HMM-based segmentation. For the latter, we remove the first 𝐾 principal components 
(PCs) from the read depth matrix and transform the residuals to 𝑧-scores for each sample 
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separately. The 𝑧-scores are then segmented by a HMM whose parameters are set as the default 
values in XHMM.  The specificity of both approaches is controlled to be higher than 99%.  The 
sensitivities for short CNV (5 exons) and long CNV (10 exons) at different population frequency 
levels are shown in Figure 1.6.  We see that both approaches attain high sensitivity for rare 
CNVs, and both have decreased sensitivity for common CNV events. The sensitivity of CODEX is 
higher than that of the existing approach for both rare and common variants (Figure 1.6). For 
CNV events with frequencies around 50%, both methods have the lowest power due to the fact 
that the CNV signals are falsely filtered out by a sample-wise latent factor (Figure 1.6). Also, 
shorter CNV events are more often missed by the SVD approach whereas CODEX has 
comparable sensitivity for short and long variants at this scale (Figure 1.6). 
To gain a better understanding of what the latent factors in CODEX and SVD-based 
methods are capturing, we show in Figure 1.7 the correlation of the latent factors to measurable 
quantities. The exon-wise latent factors in both models and the estimated value of 𝛽 in CODEX 
are compared to GC content, mean exon coverage, and true copy number.  The sample-wise 
latent factors in both models are compared to center, batch, population, and total coverage (𝑁). 
Based on these correlations, we make the following observations: First, mean exon coverage, 
represented by the pseudo-reference sample {(∏ 𝑌𝑖𝑣
𝑚
𝑣=1 )
1 𝑚⁄ : 1 ≤ 𝑖 ≤ 𝑛}, is captured by 𝛽 in 
(correlation coefficient 0.99) in CODEX and the first exon-wise PC in SVD (correlation coefficient 
-0.98). Exon length and capture and amplification efficiency are confounded in this exon-specific 
bias and there is no way, nor any need, to estimate these individual quantities separately. 
Second, GC content is correlated with the third exon-wise PC in SVD (correlation coefficient -
0.75). CODEX specifically models the GC content bias for each sample by the term {𝑓𝑗(𝐺𝐶): 1 ≤
𝑗 ≤ 𝑚}, and as we show later, the bias cannot be fully captured by a linear PC.  Third, a CNV that 
is more frequent in the population has higher absolute correlation between copy number state 
and the exon-wise latent factors in both CODEX (-0.22) and SVD (0.57). This is why sensitivity is 
lower for common CNVs. Finally, other known sources of bias, such as sequencing center and 
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batch, are captured by sample-wise latent factors in both CODEX (correlation coefficient -1 and 
0.74) and SVD (correlation coefficient 0.97 and -0.71).  In this data set, population doesn’t seem 
to be captured by any of the top latent factors. 
1.2.6 Analysis of Whole Exome Sequencing of Neuroblastoma 
We also analyze a WES data set consisting of 222 paired tumor/normal (blood leukocyte) 
samples of individuals older than 18 months of age at diagnosis with stage-4 neuroblastoma from 
the TARGET Project (33). WES of native and whole genome amplified DNA of ~33Mb regions 
yields a 124X average coverage, with 87% of bases suitable for mutation detection (33). Our 
discussion here focuses on the well characterized ATRX gene region (33-35). The TARGET 
Project reported recurrent focal deletions with a complex nested structure spanning the ATRX 
gene.   Since there are matched normal samples for this study that have also been sequenced by 
the same technology, the TARGET calls were made by comparing each tumor sample to its 
matched normal.  This allows us to compare the effectiveness of CODEX’s normalization model 
to that of taking a log ratio to the matched normal coverage.  Also, focusing on this well 
characterized region allows us to demonstrate in accuracy of CODEX for handling recurrent 
complex nested events. 
The RPKM (reads per kilo bases per million reads) for each exon and each sample are 
plotted in Figure 1.8a. The RPKM profiles are very noisy and do not show any clear decrease in 
this region in any of the samples, highlighting the need for normalization. For comparison, we 
also show the TARGET Project's initial analysis, which reported 16 multiexon deletions within 
ATRX by comparing tumor to matched normal samples (33). Specifically, we repeat their analysis 
by thresholding the log2-ratio of RPKM in tumor to RPKM in normal samples, illustrated in Figure 
1.8b. Figure 1.8c shows the normalized intensities given by CODEX, which detects 18 samples 
with somatic focal deletions. We also apply XHMM to the tumor data set and detect 14 samples 
with focal deletions (Figure 1.8d). 
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Of the 18 samples with somatic deletions detected by CODEX, three are also called by 
the TARGET Project but missed by XHMM; one is detected by XHMM and CODEX with exactly 
the same breakpoints but is missed by the Target Project; one is uniquely called by CODEX 
(Table 1.3a). The sample uniquely called by CODEX is a small deletion that overlaps significantly 
with deletions called in other samples.  Detailed CNV calling and genotyping results by each 
method are in Table 1.3b-d and the genome-wide blood and tumor CNV events discovered by 
CODEX are summarized in Table 1.4. The comprehensive analysis results will be published 
separately. 
It is clear by visual comparison of Figure 1.8c to Figure 1.8b and Figure 1.8b that the 
read depth normalization method within CODEX gives better signal to noise ratio than the SVD 
based normalization method in XHMM (note the difference in range of the y-axes) and also better 
than the commonly prescribed method of normalizing to matched normal controls. This illustrates 
that by borrowing information across a large cohort, the estimated control coverage of ?̂? from our 
normalization model is more effective in capturing the biases in whole exome sequencing than 
the matched normal. Whereas the matched normal sample is important to distinguish between 
germline and somatic variants, CODEX's normalization procedure can be used in case of 
unavailability of blood samples or contamination of blood samples from circulating tumor cells.  
When matched normal is available, somatic status can be determined by comparing CODEX calls 
in tumor to those in normal.  This example also shows that CODEX's segmentation algorithm 
performs well in detecting multiexon CNVs with a nested structure, and that it successfully 
detected a rare CNVs (18/222=8.11%) in a clinical setting. 
1.3 Discussion 
Here we propose CODEX, a normalization and CNV detection method for WES data. CODEX 
includes a normalization model with non-parametric functional terms for GC content and Poisson 
latent factors for biases that are not directly quantifiable. We show that both parts of the 
normalization model are necessary for WES data. CODEX segments the genome using a 
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Poisson likelihood model based on the control coverage ?̂? estimated during the normalization 
step.  CODEX can be applied to both normal and tumor genome analysis. 
We show through several data sets that CODEX's multi-sample normalization procedure 
offers higher sensitivity and specificity for detection and genotyping of both common and rare 
CNVs. The distinguishing features of CODEX compared to existing methods are: (i) CODEX 
doesn’t require matched normal samples as controls for normalization; (ii) The Poisson log-linear 
model fits better with the WES count data than SVD approaches; (iii) Dependence on GC content 
is modelled by a flexible nonparametric function in CODEX allowing it to capture non-linear 
biases; (iv) CODEX implements the BIC criterion for choosing the number of latent variables, 
which gives a conservative normalization on simulated and real data sets; (v) Compared to HMM-
based segmentation procedures, the segmentation procedure in CODEX is completely off-the-
shelf and doesn’t require large relevant training set; (vi) CODEX estimates relative copy number, 
which can be converted to genotypes by thresholding, rather than broad categorizations (deletion, 
duplication, and copy number neutral states). 
We carry out simulation studies by spiking in CNV signals to WES read depth data from 
copy-number-neutral regions. We show that CODEX has higher power compared to SVD based 
method followed by HMM, although both methods suffer from common CNV events. We also 
investigate the nature of the exon- and sample-wise terms and Poisson factors in CODEX, PCs 
extracted by SVD, and other directly known biases and artifacts. We show that PCs from SVD 
obtained by unsupervised learning are correlated by the terms specifically modelled and 
quantified by CODEX and that the GC content correlates with one PC from SVD with correlation 
coefficient -0.75, which, again, is specifically modelled by CODEX. Developing a robust method 
that can detect common CNVs from background noise with high sensitivities may be a future 
direction to get focused on. 
We compare CODEX’s performance against direct calling results from other existing 
methods on the 1000 Genomes Project WES data set and show that CODEX is more accurate by 
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comparing CNV calls by WES against three gold standard SNP array CNV call sets. Since 
CoNIFER and EXCAVATOR detect a significant proportion of CNVs with lengths greater than 200 
kb whereas CODEX and XHMM return much shorter CNVs (Figure 1.4), we don’t exclude any 
CNV calls by SNP arrays so as to get more “reliable” gold standards as does Fromer et al. (28), 
despite the fact that array based methods, when compared to next-generation sequencing, don’t 
have as good resolutions. This might explain why the overall sensitivity/recall rates are no larger 
than 0.6 for all methods (Figure 1.5, Table 1.2). Another possible explanation lie in that due to the 
discrete nature of WES data, read depth is used as the only inference to detect CNVs, which has 
only exon-level resolution and thus lower power in detecting short CNVs compared to split-read 
and paired-end-mapping methods developed for WGS. Despite the limitations, WES has been 
used and is still being used as a preferred method of choice for large-scale studies.  
With a clinically relevant example on detecting rare somatic CNVs within ATRX 
associated with neuroblastoma, CODEX is shown to be applicable to a wide range of study 
designs for CNV detection using WES data. Specifically, we show that CODEX doesn’t require 
matched normal controls for normalization and is able to detect previously reported CNVs within 
tumor samples more accurately compared to SVD-based method. Matched blood samples, when 
available, can be used to distinguish somatic CNVs from germline ones. However, under most 
circumstances, the normal samples are often unavailable, incomplete, or unmatched, which 
drives the need for normalization using cases only. The genome-wide CNV results based on this 
data set are available and will be compared against other metrics (matched microarrays, whole-
genome sequencing, RNA-sequencing, etc.) and validated on bench. The comprehensive 
analysis results will be published elsewhere. 
1.4 Methods 
1.4.1 Sample Selection and Target Filtering 
To have as much sample- and exon-wise homogeneity as possible and to make sure that our 
normalization algorithm converges without being deviated by extreme values, we adopt a sample 
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selection and target filtering strategy before applying our proposed normalization method to the 
read depth data. Specifically, for reducing artifacts, we recommend that all of the samples be 
sequenced by the same platform. We further filter out exons that: (i) have extremely low coverage 
(median read depth across all samples less than 20, which mostly reflect capture failure); (ii) are 
extremely short (less than 20 base pairs); (iii) are hard to map (mappability less than 0.9); (iv) 
have extreme GC content (less than 20% or greater than 80%). These default thresholds for 
quality control (QC) are recommended but are also user-tuneable and thus can be adapted to 
different sequencing protocols.  We show in Table 1.1 that with the above QC thresholds, 9.74% 
of exon targets are excluded in the data. Details on computation of GC content, mappability, and 
depth of coverage are provided in 1.4.2 Depth of Coverage, GC Content, and Mappability. 
1.4.2 Depth of Coverage, GC Content, and Mappability 
Depth of coverage for each exon is computed as the number of reads (with mapping quality 
greater than a user-defined threshold) that overlap with the exon. To calculate the exonic 
mappability, we first construct consecutive reads that are one base pair (bp) apart along the exon. 
The length of the reads is set to be the same as that from the sequencing technology and the 
sequences are taken from the hg19 reference. We then find possible positions across the 
genome that the reads can map to allowing for a default number of mismatches (2 for the 1000 
Genomes Project data set in our study which has read 100). Finally we compute the mean of the 
probabilities that the overlapped reads map to the target places where they are generated and 
use this as the mappability of the exon. 
We compare our computed exonic mappability with the number of overlapped segmental 
duplications from the Segmental Duplication Database. Results show that not all segmental 
duplication regions are hard to map and thus it is not wise to directly filter out exons that overlap 
with segmental duplications (Figure 1.9a). As a comparison, we also compute the sequence 
complexity—percentage of bases within exons soft masked by RepeatMasker 
(http://www.repeatmasker.org/) using PLINK/SEQ (http://pngu.mgh.harvard.edu/purcell/plink/), 
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which is the filtering strategy adopted by XHMM. It turns out that not only XHMM has an overly 
stringent threshold on sequence complexity/mappability (Figure 1.9b), but also it includes other 
outlier removal steps, such as removing samples with coverage that are empirical outliers, 
filtering out targets with a standard deviation of PCA-normalized z-score greater than 30, etc. 
These additional empirical ways of excluding samples and targets might treat true signals as 
outliers and remove them. 
1.4.3 Poisson Latent Factors and Choice of K 
Some sources of bias in whole exome sequencing can be directly measured (GC content, 
mappability, and exon size).  However, there are other unmeasurable sample- and target-specific 
biases that are amplified during the library preparation and sequencing experiment. The latent 
Poisson factors {𝑔𝑖𝑘} and {ℎ𝑗𝑘} are designed to capture and decompose these unobserved 
systemic bias in a log-additive manner. Such latent factor models have been shown to be 
effective in the analysis of microarray data (44-47), and have also recently been applied to NGS 
data. Both CoNIFER (26) and XHMM (28) use latent factor models to remove systemic bias, but 
their models assume continuous measurements with Gaussian noise structure, while CODEX is 
based on a Poisson log-linear model, which is more suitable for modeling the discrete counts in 
WES data, especially when there is high variance in depth of coverage between exons. The 
latent factor terms in the normalization model resemble those used in Lee et al. (37) for 
microRNA profiling. In particular, the identifiability constraints in Lee et al. also apply to our case, 
and our iterative maximum-likelihood estimation procedure ensures identifiability. 
A common downfall of latent factor models is that true CNV signals may correlate with 
and influence the top 𝐾 latent factors. Thus, the number of latent factors, 𝐾, is a crucial 
parameter. If 𝐾 is chosen to be too large, some bona fide CNV signals, especially those for 
common CNVs, will be dampened during normalization. On the other hand, if 𝐾 is too small, 
residual artifacts will remain and inflate the type I error rate. CoNIFER (26) adopts a common 
practice for choosing the number of factors in latent variable models, which is to draw the scree 
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plot with the number of components on the X-axis and the corresponding contributed variance on 
the Y-axis. If there is an “elbow” in the scree plot, then 𝐾 is chosen at the position of the elbow 
(Figure 1.10a). However, in most cases there is no detectable elbow, which is why many existing 
methods arbitrarily set the value of 𝐾. XHMM (28) removes components with variance 0.7 𝑚⁄  or 
higher, where 𝑚 is the number of components (samples) and 0.7 is a user-tuneable parameter 
arbitrarily set as default. 
We apply two additional statistical procedures of choosing this crucial model tuning 
parameter: Akaike information criterion (AIC, Figure 1.10b) and Bayes information criterion (BIC, 
Figure 1.10c). 
AIC = 2 ln(𝐿) − 2𝑘 
BIC = 2 ln(𝐿) − 𝑘 ln(𝑛) 
where 𝐿 is the likelihood for the estimated model, 𝑘 is the number of parameters in the model, 
and 𝑛 is the number of data points. Both criteria reward goodness of fit with a penalty term that is 
an increasing function of the number of parameters in the model. AIC penalizes the number of 
parameters less strongly than does BIC, and thus the model chosen by AIC removes more latent 
factors than that chosen by BIC.  CODEX reports all three statistical metrics (AIC, BIC, 
percentage of variance explained) and uses BIC as the default method to determine the number 
of 𝐾. Since false positives can be screened out through a closer examination of the post-
segmentation data, whereas CNV signals removed in the normalization step cannot be 
recovered, CODEX opts for a more conservative normalization that, when in doubt, uses a 
smaller value of 𝐾. 
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Figure 1.1: A flowchart outlining the procedures of CODEX in normalizing WES read depth 
and calling CNV. The first step is computing GC content, mappability, and depth of coverage 
using Rsamtools with QC measures. The multi-sample normalization model by CODEX is then 
applied to remove biases and artifacts introduced by GC content, exon targeting and amplification 
efficiency, and latent systemic artifacts. The Poisson likelihood-based segmentation algorithm 
gives final CNV calls with copy number estimates. 
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Figure 1.2: Predicted values of 𝒇(𝑮𝑪) for 4 samples from the 1000 Genomes Project data 
set. Most patterns agree with previous observations that read depth has a unimodal relationship 
with GC content. However, dual modality is also observed. Furthermore, the function changes in 
shape and not just by a scaling factor. 
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Figure 1.3: ROC curves of read depth normalization by CODEX and SVD-based method. 
Gold standard is taken from the International HapMap Consortium SNP array CNV call set. The 
input for CODEX is the log2-ratio of the original read depth 𝑌 versus the estimated control 
coverage ?̂?; the input for SVD-based method is the residual obtained by subtracting the principal 
components from the original read depth 𝑌. For common CNVs shown in (a), (b), and (c), CODEX 
performs significantly better since SVD-based methods are optimized for rare CNV detection; for 
rare CNVs shown in (d) and (e), the two methods tend to have similar power for rare 
heterozygous deletions whereas CODEX performs better in detecting rare duplications. Of the 90 
samples we analyze, there is no rare heterozygous deletion from the HapMap call set that we can 
use as a gold standard. 
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Figure 1.4: Lengths of CNV calls by CODEX, XHMM, CoNIFER, and EXCAVATOR. Genomics 
lengths of CNVs (a) and number of exons in CNV regions (b) are compared across four different 
methods. CODEX and XHMM detects more short CNVs whereas CoNIFER and EXCAVATOR 
return significant proportion of CNVs with lengths greater than 200 kb/20 exons. 
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Figure 1.5: Assessment of CNV calls on the 1000 Genomes Project by array-based 
methods. CNV calls by CODEX, XHMM, CoNIFER, and EXCAVATOR are validated against 
genotyping calls from International HapMap Consortium (a), Conrad et al. (b), and McCarroll et al. 
(c). CODEX returns well-balanced precision and recall rates with highest F-measures (grey 
contours shown harmonic means of precision and recall rates) among all methods for detection of 
common, rare, and all CNVs. 
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Figure 1.6: Power analysis of CODEX and SVD-based method on simulation data set. 
Sensitivities are obtained by averaging results from 10 simulations. Both methods suffer from 
“common” CNV events (CNVs with frequencies around 50%). When CNV frequency exceeds 
50%, deletions and copy-neutral states are detected as copy-neutral states and duplications 
instead, which recovers the sensitivities. CODEX performs better compared to SVD-based 
methods with higher power. Longer CNVs are generally easier to be detected. 
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Figure 1.7: Correlation matrix plot of biases and artifacts shown in both exon-wise and 
sample-wise fashion. 𝛽, exon-wise latent factors, GC content, copy-number state, and pseudo-
reference genome are interrogated in (a) and (c). Sample-wise latent factors, total number of 
reads per sample, sequencing centers, batch effects, and population are shown in (b) and (d). (a) 
and (b) are for spike-in CNV events with frequency 0.1 and (c) and (d) are for spike-in CNV 
events with frequency 0.4. 𝛽 and first exon-wise PC in SVD highly correlate with pseudo-
reference genome. GC content is correlated with the third exon-wise PC in SVD with correlation 
coefficient -0.75. Copy-number states show higher correlation for spiked-in CNVs with higher 
frequencies. Sequencing centers and batch effects are captured by latent factors whereas 
population doesn’t seem to add too much variation to the CNV signals.  
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Figure 1.8: Detection of rare somatic deletions within ATRX by WES of 222 neuroblastoma 
matched tumor/blood samples. Location of ATRX is shown as blue bars in c and d. (a) RPKM 
computed from the tumor samples. There is no clear visual indication of presence of somatic 
CNVs from these raw quantities. (b) Log2-ratio of tumor versus blood read depth. Initial analysis 
by the TARGET Project did careful inspection of these values and discovered 17 samples with 
focal deletions. (c) log2-ratio of the original tumor read depth 𝑌 versus the estimated control 
coverage ?̂?  (model fitted on tumor data set only) by CODEX. Poisson likelihood-based 
segmentation algorithm by CODEX discovers 18 samples (red bars) with somatic deletions that 
exhibit a nested structure across samples. The 4 samples that are called by CODEX but not by 
XHMM are colored in red in the embedded window. (d) XHMM's direct output: z-scores 
normalized by principal component analysis. The HMM calling algorithm by XHMM detects 14 
samples (red bars) with somatic deletions. 
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Figure 1.9: Filtering strategies on mappability and sequence complexity by CODEX and 
XHMM. Computation results from chromosome 22 are shown with filtering thresholds in dashed 
lines. (a) Mappability computed by CODEX. Exons that overlap with previously reported 
segmental duplications are marked in red. (b) Sequence complexity used in pre-filtering step by 
XHMM. 
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Figure 1.10: Choice of 𝑲, number of latent Poisson factors. Remaining variance in the read 
depth data (a), AIC (b), and BIC (c) are used as three different metrics, which yield similar models 
with 𝐾 optimally set at 3 or 4. Each line represents result of one chromosome. Suggested 𝐾 is 
agreeable across the genome. 
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Table 1.1: CNV call sets information on the 1000 Genomes Project WES data set. Number of 
exon targets before and after QC procedure is shown. CNVs detected by CODEX, XHMM, 
CoNIFER, and EXCAVATOR are shown and are further categorized into common and rare ones 
(common-rare in parentheses). Number of latent factors (𝐾) and principal components (PCs) are 
shown for latent factor models: default values from CODEX and XHMM are adopted; number of 
PCs for CoNIFER is chosen at 4 so that it is conservative by the scree plot and is comparable to 
XHMM. a Excluded due to mis-handling of sex chromosomes by EXCAVATOR. 
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Table 1.2: Sensitivity, specificity, and precision rate of CNV calls by CODEX, XHMM, 
CoNIFER, and EXCAVATOR. The plot of precision and recall rates are shown in Figure 5. Three 
“gold-standard” CNV metrics are adopted from (a) International HapMap Consortium, (b) Conrad 
et al., and (c) McCarroll et al.. CODEX and XHMM performs better in detecting rare CNVs 
compared to common ones, with CODEX having the highest F-measure among all methods 
compared. 
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(a) 
 
(b) 
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(c) 
 
(d) 
 
 
Table 1.3: Somatic deletions within ATRX region detected using WES data of 
neuroblastoma patients. (a) Summary of deletions detected by tumor/normal threshold, 
CODEX, and XHMM with break-point and length information. Of the 18 samples detected by 
CODEX, 16 samples overlap with the matched tumor blood analysis result; 14 and all of XHMM’s 
CNV events are detected; one sample is uniquely called. Breakpoints may differ slightly between 
different methods but are within reasonable limits. (b) Deletions detected by thresholdhing log2-
ratio of tumor RPKM to blood RPKM. (c) Deletions detected using tumor samples only by 
CODEX. (d) Deletions detected using tumor samples only by XHMM. 
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Table 1.4: Genome-wide CNVs detected by CODEX of the neuroblastoma data set. Blood 
and tumor CNVs are reported separately by chromosome. 
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Chapter 2  
ASSESSING INTRA-TUMOR HETEROGENEITY AND TRACKING LONGITUDINAL AND 
SPATIAL CLONAL EVOLUTIONARY HISTORY BY NEXT-GENERATION SEQUENCING 
2.1 Introduction 
It has been long recognized that cancer is a disease driven by genetic and epigenetic alterations 
(48-50). These alterations confer upon its carrier cell selective advantage, and rounds of 
Darwinian selection produce tumor cell populations with aggressive phenotypes. High-throughput 
sequencing technologies have made possible the large-scale, high-resolution analysis of tumor 
genomes. A recurring finding of these studies is the high degree of heterogeneity – both inter-
tumor heterogeneity among patients with the same clinical diagnosis (51, 52), as well as intra-
tumor heterogeneity between tumor cells derived from the same patient (summarized in Table 
2.1) (53-59). Heterogeneity, at all levels, confound diagnosis and treatment. Most large-scale 
studies to date, for example those led by the Cancer Genome Atlas Research Network (51) and 
the International Cancer Genome Consortium (52) have focused on inter-tumor heterogeneity. 
These studies typically collect and sequence bulk tissue data, usually one sample per patient, 
and compare the mutation profiles across patients. This study design is not optimized for the 
study of intra-tumor heterogeneity, which has thus received, until recently, comparatively less 
attention. 
When only one sample from a tumor is sequenced, early analyses of intra-tumor 
heterogeneity started with the estimation of normal cell contamination and tumor ploidy (60, 61). 
For example, ABSOLUTE, one of the earliest methods, classifies mutations as clonal or subclonal 
after adjusting for the estimated purity and ploidy of the sample. Most approaches for the 
detection of subclonal mutations treat point mutations and copy number aberrations separately 
(62-65). In the case of point mutations, i.e. single-nucleotide alterations (SNAs) and small 
insertions and deletions (indels), most methods rely on mixture models for the variant allele 
frequency (VAF) under the assumption that mutations carried by the same set of cells have the 
same VAF. But the VAF is also affected by the copy number of the region where the point 
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mutation resides, and copy number aberrations (CNAs) are prevalent in cancer. Recently, Li and 
Li (66) and Deshwar et al. (67) proposed models for joint inference of SNAs and CNAs. Li and Li 
(66) further gave important insight into the identifiability of the underlying parameters, if one were 
to analyze each mutation locus separately. The many unknowns, including the number of 
subpopulations in the tumor, the mutation profile of each subpopulation and its contributing 
proportion to the sample, and the phasing of aberrations that affect the same genome locus make 
the estimation problem challenging in all but the simplest scenarios, if one were to sequence only 
one bulk DNA sample from the tumor. We will discuss these underlying challenges through a 
more thorough literature review after giving a more detailed formulation of the problem. 
 Ultimately, tumor evolution occurs at the single-cell level, and single-cell methods provide 
a powerful approach to assess tumor heterogeneity without the confounding effects of mixed cell 
populations (53, 68). Despite its promise, single-cell DNA sequencing data are much noisier than 
bulk sequencing data due to allele dropout events and amplification errors (69), and furthermore, 
the per-cell coverage is still limited due to constraints on budget and labor.  While these single-
cell sequencing studies have improved our understanding of intra-tumor heterogeneity, most 
current tumor studies still sequence the DNA at the bulk tissue level. 
 Recently, there have been increasing efforts to sequence the tumor from the same 
patient at multiple time-points and/or from multiple spatially separated resections (54-59). Multiple 
snapshots of the same tumor have proved invaluable for identifying subclonal populations and for 
inferring the tumor’s evolutionary history. Multi-dimensional scatterplots of VAFs allow higher 
resolution for cluster detection than the one dimensional histogram in the single-sample case. 
Recent methods, such as Pyclone (62) and SciClone (63), apply Bayesian mixture models to 
detect these clusters. LICHeE (70) and SCHISM (71) infer phylogeny from VAFs as an acyclic 
directed graph network. Another recent work, Clomial (72), showed that it is possible to obtain 
precise and informative estimates of the underlying subpopulations through a matrix 
deconvolution framework. One practical drawback of Clomial (72) is that it takes only SNA input 
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and assumes that all mutational loci are heterozygous from copy number neutral regions. 
SCHISM (71), BitPhylogeny (73), PhyloWGS (67), and SPRUCE (74) adjust for CNAs in their 
model in different ways, but these methods still require limiting assumptions and do not make full 
use of the data, as we discuss in detail a bit later. 
Here, we focus on the analysis of intra-tumor heterogeneity by multi-sample bulk DNA 
sequencing of tumor samples. We propose Canopy (copy number and single nucleotide 
alteration analysis of tumor phylogeny) (75), a statistical framework and computational procedure 
for identifying the subpopulations within a tumor, determining the mutation profiles of these 
subpopulations, and inferring the tumor’s phylogenetic history. The input to Canopy are VAFs of 
somatic SNAs along with allele-specific coverage ratios between the tumor and matched normal 
sample for somatic copy number calls. These quantities can be directly taken from the output of 
existing software. Canopy provides a general mathematical framework for pooling data across 
samples and sites to infer the underlying phylogeny. For SNAs that fall within CNA regions, 
Canopy infers their temporal ordering and resolves their phase.  When there are multiple 
evolutionary configurations consistent with the data, Canopy attempts to explore all configurations 
and assess their confidence. 
Identifiability of the underlying evolutionary process and confidence in its reconstruction is 
an important aspect of consideration. The Bayesian framework for Canopy allows assessment of 
the quality of inference. The resolution at which clones can be differentiated depends on the data, 
and in particular, on how many slices of the tumor are taken, how genotypically different these 
slices are to each other, and sequencing depth.  As the number of clones increase, the proportion 
of cells attributable to at least some of the subclones would necessarily decrease, and thus, the 
higher sequencing depth would be needed to detect mutations present in those clones.  Under 
the Bayesian framework, the resolution of our estimates and the confidence in our conclusions 
can be quantified by the posterior distribution.  
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2.2 Results 
We will start by giving a more precise formulation of the clonal decomposition problem along with 
a more in-depth discussion of existing methods and their key assumptions. We will show that, 
under our formulation, the likelihood of the observed sequencing data can be written in matrix 
form and be decomposed into terms that reflect the tumor’s phylogenetic history, the phasing of 
overlapping SNAs and CNAs, and the contributing proportions of the admixed cell populations. 
Canopy assumes non-informative priors for the unknowns in the model, and explores their 
possible values by Markov chain Monte Carlo (MCMC). Through simulations, we explore the 
effects of various parameters on deconvolution accuracy, and compare Canopy against existing 
methods. Canopy is then applied to four datasets with different sequencing designs: the whole-
exome sequencing of a heterogeneous triple-negative breast carcinoma cell line MDA-MB-231 
and its derived sublines with single and mixed cell populations, the whole-genome sequencing of 
breast cancer patient xenografts from Eirew et al. (57), the whole-genome sequencing of a 
leukemia patient at two time-points from Ding et al. (54), and the multi-region sequencing of an 
ovarian cancer patient from Bashashati et al. (55).  
2.2.1 Modeling of SNAs, CNAs, and Clonal Tree 
Figure 2.1a shows the phylogeny of an evolving tumor, which starts from a diploid normal cell and 
progresses through waves of somatic mutations. The tumor’s evolution is depicted as a 
bifurcating tree, with the ancestral normal cell population at the root, and accumulating mutations 
along its branches. Time runs vertically down the tree from the root, and when a sample of the 
tumor is taken at any point in time, the tree is sliced horizontally, cutting the branches to form 
leaves. The subpopulations within the sample are represented by the “leaves” in that slice. Each 
subpopulation contributes a fraction of cells to the sample, which, taken together, are represented 
by a vector of non-negative numbers that sum to one. To model normal cell contamination we 
restrict the left-most branch of the tree to be non-bifurcating and mutation-free. Thus, the 
proportion of normal cells within any sample is simply the first entry in its mixture proportion 
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vector. Multiple samples collected for the same tumor are represented by multiple horizontal 
slices of the phylogeny, each receiving its own vector of proportions. 
The observed data is summarized in Figure 2.1b. We let 𝑁 be the number of samples, 
and 𝑆 and 𝑇 be the number of somatic SNAs and CNAs, respectively, that were called across all 
samples. For SNAs, let the matrices 𝑅 ∈ ℝ𝑆×𝑁 and 𝑋 ∈ ℝ𝑆×𝑁 be, respectively, the number of 
reads containing the mutant allele and the total number of reads covering each of the 𝑆 loci in 
each of the 𝑁 samples. The ratio 𝑅/𝑋 is the proportion of reads supporting the mutant allele, 
known as the variant allele frequency (VAF).  For CNAs, Canopy directly takes output from 
FALCON (76), FALCON-X, or other allele-specific copy number estimation methods (77). These 
outputs are in the form of estimated major and minor copy number ratios, denoted by 𝑊𝑀 ∈ ℝ𝑇×𝑁 
and 𝑊𝑚 ∈ ℝ𝑇×𝑁 respectively, with their corresponding standard errors 𝜀𝑀 ∈ ℝ𝑇×𝑁 and 𝜀𝑚 ∈ ℝ𝑇×𝑁. 
See 2.4.1 Allele-Specific Copy Number for details regarding these quantities. For each SNA and 
each CNA, we also know whether they overlap. This information is represented by the matrix 𝑌 ∈
ℝ𝑆×(𝑇+1): for column 𝑗 + 1, 𝑌 has 1’s for SNAs that lie within CNA 𝑗 and 0’s for all other SNAs; as 
first column, 𝑌 has 1’s for SNAs that don’t reside in any CNAs and 0’s otherwise (see example in 
Figure 2.1b). 
Each sample contains a mixture of the clones that comprise the tumor, and thus these 
observed VAFs and copy number ratios rely on the mixture proportions as well as the genomic 
profiles of the clones, as embodied by the underlying phylogenetic tree that is shared across all 
samples collected for the same tumor. 
2.2.2 Relationship to Existing Work 
Many existing studies of tumor evolution by multi-region or multi-time-point bulk tumor DNA 
sequencing rely on laborious manual history reconstruction (54, 55). There have been much 
recent progress in the development of computational approaches for the analysis of such data. 
These approaches differ in the types of mutations that are modeled and the assumptions that are 
made. The main differences are summarized in Table 2.2 and discussed below. 
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TITAN (64) and THetA (65) focus on estimating cell population structure and recovering 
clonal evolutionary history for the case where somatic CNAs and loss of heterozygosity (LOH) 
distinguish subpopulations. These methods use allelic read coverage at germline heterozygous 
SNP loci to distinguish clonal versus subclonal CNA events. They ignore SNAs, and do not pool 
data across multiple samples from the same tumor. 
Many programs focus specifically on SNAs. For example, SciClone (63) clusters the 
VAFs of SNAs in copy-number neutral and LOH-free portions of the genome using a Bayesian 
beta mixture model. Pyclone (62) is an extension of SciClone that adds prior information elicited 
from copy number estimates obtained from either genotyping arrays or whole-genome 
sequencing to its Bayesian nonparametric clustering method. Neither SciClone (63) nor Pyclone 
(62) infers the phylogenetic relationship between subclones. LICHeE (70) and SCHISM (71) take 
VAFs of SNAs as input and construct a phylogenetic tree via an acyclic directed graph. Clomial 
(72), another program designed exclusively for SNAs, performs mixture deconvolution assuming 
that all mutational loci are heterozygous from copy number neutral regions. Clomial decomposes 
the VAF matrix into a product of sample proportions and population genotypes, and uses 
expectation maximization (EM) to estimate both matrices. 
ABSOLUTE (60) was the first software to infer subclonal heterozygosity from both SNAs 
and CNAs. However, taking data from only one sample, it determines whether each event is 
clonal or subclonal, but does not attempt to genotype or quantify the underlying subclones. In a 
similar fashion, Lonnstedt et al. (78) took a two-step approach using both SNA and CNA input, 
first estimating CNAs and then comparing VAF of SNA to its local copy number estimate to 
classify the somatic point mutation as clonal or subclonal. Recent approaches such as 
BitPhylogeny (73) and PhyloSub (79) detect major subclonal lineages by sampling the subclonal 
proportions via a tree-structured stick-breaking (TSSB) process, adjusting for overlapping CNAs. 
BitPhylogeny further adapts the nonparametric Bayesian mixture model to DNA methylation data 
from multiple microdissections from different regions of the same tumor. 
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As mentioned earlier, the VAF, which quantifies the proportion of alleles in the sample 
carrying a somatic mutation in the sample’s DNA pool, is not the same as the proportion of cells 
in the sample carrying the somatic mutation. We call the latter, which is not directly observed in 
sequencing data, the mutant cell frequency (MCF). A similar quantity that is sometimes used in 
literature is cancer cell fraction (CCF), which is the proportion of cells among all cancer cells 
carrying the mutation. Given the tumor purity 𝜙𝐶, 𝑀𝐶𝐹 = 𝐶𝐶𝐹 × 𝜙𝐶. The MCF of a mutation 
directly reflects the total contributing proportion of the clone(s) that carry it, but to compute MCF 
from VAF, one needs to compensate for any CNAs that affect the locus. The existing methods 
differ by how this compensation is done. ABSOLUTE (60), EXPANDS (61), Pyclone (62) and 
PhyloSub (79) assume that when a CNA event overlaps a SNA, the point mutation resides in a 
region with homogeneous aneuploidy, a scenario where no subclonal CNA events are allowed. Li 
and Li (66) conducted a detailed analysis of the complete set of scenarios covering the possible 
order and phase of overlapping SNAs and CNAs in developing their software CHAT. However, 
CHAT does not pool information across sites or across samples. PhyloWGS (67) also conducts a 
detailed breakdown of the possible configurations of overlapping SNA and CNA and is the first 
method to integrate both types of mutations when reconstructing cancer phylogenies using a 
TSSB.  However, for each CNA region, PhyloWGS requires as input the integer absolute copy 
number of each allele and treats CNA events as pseudo-SNA events to compute its MCF. Since 
knowing integer-valued copy number is akin to knowing the clonal decomposition, in essence, 
PhyloWGS requires a two-step procedure where the underlying clones are first identified with 
their absolute copy numbers estimated using CNA data only, and this information is then used to 
compute the MCF of SNAs. SPRUCE (74) is another recent method that analyzes both SNAs 
with CNAs and characterizes the tumor phylogeny as a restricted class of spanning trees. Like 
PhyloWGS, SPRUCE takes processed CNA calls, e.g. from THetA, and assumes known MCF for 
CNA events. Unlike these existing approaches, Canopy takes as input raw copy number ratios 
estimated by existing segmentation programs, and uses SNAs and CNAs to jointly infer the 
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underlying clones and their evolutionary history. Since the same clonal admixture underlie CNAs 
and SNAs, this integrated approach achieves more accurate estimates in complex scenarios, as 
we illustrate later through examples. 
As with all phylogenetic inference, assumptions are needed to resolve ambiguity. The 
perfect phylogeny model (70, 80) assumes that all subclones share the same phylogenetic tree 
and that mutations don’t recur independently in different subclones, that is, each mutation 
appears only once and once it appears, it does not revert back to its original state. This no-
homoplasy assumption, also referred to as the infinite sites assumption (67, 81), is adopted by 
most methods to allow model identifiability. For example, it is possible to assert that under the 
infinite sites assumption, mutations with lower CCFs cannot be ancestral to mutations with higher 
CCFs. To deal with copy number changes, El-Kebir et al. (74) proposed instead an infinite alleles 
assumption, or the multi-state perfect phylogeny, where a mutation may change state more than 
once on the tree due to gain or loss of copy number, but changes to the same state at most once. 
Furthermore, Deshwar et al. (67) introduces the ‘weak parsimony’ assumption, which posits that 
mutations with similar CCFs across all samples lie on the same branch segment in the 
phylogeny. Canopy relies on both the infinite sites assumption and the weak parsimony 
assumption, but takes a different approach from El-Kebir et al. (74) in modeling CNAs: Canopy 
extends the infinite sites assumption to CNAs by assuming that copy number events with the 
exact same breakpoints and resulting in the same copy number must be the same mutation event 
that occurs exactly once in the tumor’s evolution. CNAs that overlap but have different 
breakpoints or different copy number states are treated as separate events. For example, a 
homozygous deletion nested within a heterozygous deletion, or a series of nested amplifications, 
are treated as separate events rather than separate alleles of the same mutation. This 
assumption allows Canopy to, with appropriate data, resolve the evolutionary relationship 
between overlapping copy number events, as we show in the whole-exome study of breast 
cancer cell line MDA-MB-231. 
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2.2.3 Matrix Representation of a Tumor’s Clonal Composition 
We use 𝐾 to denote the total number of clones of the tumor that have representation among the 
cells in our sample(s). As shown in Figure 2.1a, the tumor’s evolutionary history is denoted by 𝜏𝐾, 
a bifurcating tree with 𝐾 leaves and with point mutation and copy number events assigned to its 
branch segments.  Any 𝜏𝐾  gives us three matrices reflecting the mutation profiles of the 
underlying clones, shown in Figure 2.1c: The SNA genotypes 𝑍 ∈ ℝ𝑆×𝐾, where 𝑍𝑠𝑘 is the indicator 
of whether the 𝑠th SNA is present at the 𝑘th clone, and the major and minor copy numbers ?̃?𝑀 ∈
ℝ𝑇×𝐾 and ?̃?𝑚 ∈ ℝ𝑇×𝐾, where ?̃?𝑡𝑘
𝑀 and ?̃?𝑡𝑘
𝑚 are integer-valued major and minor copy numbers of the 
𝑡th CNA in the 𝑘th clone. Phylogenetic restrictions are imposed by Canopy in that there is a one-
to-one mapping between the positions of SNAs and CNAs on the tree as well as the major and 
minor copies of CNA events and the matrix 𝑍, ?̃?𝑀, and ?̃?𝑚. Furthermore, since the left most clone 
in the tree represents the normal cells, the first column of 𝑍 contains all zeros and the first 
columns of ?̃?𝑀 and ?̃?𝑚 contain all 1’s. We do not directly observe the clones; instead, the 
samples we sequence are mixtures. We define 𝑃 ∈ ℝ𝐾×𝑁 as the clonal frequency matrix, where 
𝑃𝑘𝑗 (1 ≤ 𝑘 ≤ 𝐾, 1 ≤ 𝑗 ≤ 𝑁) is the fraction of cells in the 𝑗th sample that belong to the 𝑘th clone (𝑃 
shown in Figure 2.1a is transposed to be aligned to the phylogeny). Each column of 𝑃 sums up to 
one with the first row corresponding to the normal cell contamination. The matrices 𝑍, ?̃?𝑀, ?̃?𝑚 and 
𝑃 are all unobserved, as well as the number of clones 𝐾. Our goal is to estimate them from the 
observed data, i.e. the VAFs and the major and minor copy number ratios. 
2.2.4 SNA-CNA Phase and Combined Likelihood 
Here, we derive the likelihood for the data, given the model parameters {𝑍, ?̃?𝑀 , ?̃?𝑚, 𝑃, 𝐾}. First, 
consider the CNA events. For CNAs, multiplication (denoted by ×) of the clonal integer copy 
number matrices (?̃?𝑀 , ?̃?𝑚) and the sample proportion matrix (𝑃) gives us the continuous-valued 
major and minor copy numbers for each sample: 
?̃?𝑀 × 𝑃 = 𝐶𝑀 ∈ ℝ𝑇×𝑁
?̃?𝑚 × 𝑃 = 𝐶𝑚 ∈ ℝ𝑇×𝑁
. 
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Since the observed copy number ratios are usually computed by averaging over a large number 
of loci (for microarrays), exons (for WES), or bins (for WGS), we assume that they are normally 
distributed with the given standard errors, that is, 
𝑊𝑀~𝑁(𝐶𝑀, (𝜀𝑀)2)
𝑊𝑚~𝑁(𝐶𝑚, (𝜀𝑚)2)
. 
For SNAs, 𝑍 × 𝑃 gives the mutant cell frequency (MCF) of each SNA in each sample, 
which we denote by the matrix 𝑀𝐶𝐹 ∈ ℝ𝑆×𝑁. The observed number of mutant reads 𝑅𝑠𝑗 follows a 
binomial distribution with total count 𝑋𝑠𝑗 and probability of success being the variant allele 
frequency (VAF), which we denote by 𝑉𝐴𝐹𝑠𝑗 (1 ≤ 𝑠 ≤ 𝑆, 1 ≤ 𝑗 ≤ 𝑁). That is, 
𝑅𝑠𝑗~Binomial(𝑋𝑠𝑗 , 𝑉𝐴𝐹𝑠𝑗). 
Therefore, we need to convert 𝑀𝐶𝐹 to 𝑉𝐴𝐹 in order to calculate the binomial likelihood for SNAs.  
If all SNAs are heterozygous from copy number neutral regions, as assumed by SciClone (63) 
and Clomial (72), then 𝑉𝐴𝐹 = 1 2⁄ × 𝑀𝐶𝐹 = 1 2⁄ × 𝐶𝐶𝐹 × 𝜙𝐶, where 𝜙𝐶 is the cancer cell purity, 
𝑀𝐶𝐹 is the fraction of cells that have the SNA, and 𝐶𝐶𝐹 is the fraction of cancer cell that have the 
mutation. Pyclone (62), PhyloSub (79) and EXPANDS (61) account for CNAs but make the 
assumption that was first introduced by ABSOLUTE (60), namely that there are no subclonal 
CNA events. Therefore, 
𝑉𝐴𝐹 =
𝐶𝑚𝑢𝑡
2×(1−𝜙𝑐)+𝐶𝑡𝑜𝑡𝑎𝑙×𝜙𝐶
𝑀𝐶𝐹 =
𝐶𝑚𝑢𝑡×𝜙𝐶
2×(1−𝜙𝑐)+𝐶𝑡𝑜𝑡𝑎𝑙×𝜙𝐶
𝐶𝐶𝐹, 
where 𝜙𝐶 is the purity of cancer cells, which have a homogeneous CNA state with total copy 
number 𝐶𝑡𝑜𝑡𝑎𝑙 and mutant-allele copy number 𝐶𝑚𝑢𝑡. 
To more accurately quantify the relationship between VAF and MCF, which accounts for 
the possible phases and temporal orders of overlapping CNAs and SNAs, we consider separately 
each of the three possible underlying scenarios, which were first delineated by CHAT (66) and 
PhyloWGS (67): (i) the CNA is ancestral to the SNA (Figure 2.2a); (ii) the CNA and SNA occur in 
separate branches of the tree and thus affect separate clones (Figure 2.2b); (iii) the SNA is 
ancestral to the CNA (Figure 2.2c). To compute the 𝑉𝐴𝐹, we separately calculate the numerator 
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(copy number of the affected allele at the mutational locus), and the denominator (total copy 
number at the locus) for each SNA across all samples. The denominator can be generalized and 
is the same for all three cases, being simply the total copy number at the SNA locus. Therefore, 
the denominator is, in matrix notation, 
 
  
(𝑌 × [
𝟙
⋯
?̃?𝑀
] + 𝑌 × [
𝟙
⋯
?̃?𝑚
]) × 𝑃 ∈ ℝ𝑆×𝑁 =  
             Sample1 Sample2 Sample3
SNA1
SNA2
SNA3
SNA4
 [
           2          2           2
          1.8          1.8           1.7
          2.6           2.5           2.5
           2           2           2
          ]
, 
where 𝟙 is a vector of ones augmented to the first row of ?̃?𝑀 and ?̃?𝑚 representing the major and 
minor copy number for the ‘non-CNA’ SNA loci. The numerator differs across the three cases. 
Case 1: the CNA is ancestral to the SNA 
Only one allele of the locus is affected (e.g., SNA1 in Figure 2.2a). Therefore, the copy number of 
the affected allele for SNA 𝑠 in each clone is 𝑍𝑠,: ∈ ℝ
1×𝐾 (the 𝑠 row of the 𝑍 matrix). The 
numerator, which is the copy number of the affected allele in each sample, is thus the matrix 
product of 𝑍𝑠,: and 𝑃.  For SNA1 in Figure 2.2a, this evaluates to 
                                   Sample1 Sample2 Sample3
(𝑍1,: × 𝑃) = SNA1 [          0.3          0.5           0          ].
 
Note that the numerator in this case is the same as the row corresponding to the SNA in the 𝑀𝐶𝐹 
matrix (𝑀𝐶𝐹 = 𝑍 × 𝑃) since each variant cell has only one variant allele. 
Case 2: the CNA and SNA occur in two non-overlapping lineages 
The SNA isn’t affected by the CNA, which lies on a different branch of the tree (e.g., SNA2 in 
Figure 2.2b). Therefore, the numerator is the same as is in the previous case.  For SNA2 in 
Figure 2.2b, this evaluates to 
                                  Sample1 Sample2 Sample3
(𝑍2,: × 𝑃) = SNA2 [          0.3          0           0.5          ].
 
Case 3: the SNA is ancestral to the CNA 
This is usually the most interesting case. For example, copy number loss or LOH following an 
SNA may delete the normal allele, or copy number gain may amplify the mutated allele (e.g., 
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SNA3 in Figure 2.2c) – both scenarios having potential phenotypic consequences. Of the two 
underlying alleles at the SNA locus, we need to distinguish which has been lost and/or gained. 
That is, if the CNA confers allelic imbalance, we need to distinguish whether the major or the 
minor allele is the mutated allele. For SNA3 in Figure 2.2c, the major allele has the SNA and the 
copy number of the mutant allele in each sample, aka, the numerator, is 
{𝑍3,: ∙ (𝑌3,: × [
𝟙
⋯
?̃?𝑀
])}  × 𝑃 ∈ ℝ1×𝑁 
              Sample1 Sample2 Sample3
= SNA3 [          1.4          1.2           1.3          ]. 
  
 
Here we define the notation ∙ as element-wise matrix multiplication. If the mutant allele lands on 
the minor copy, the numerator is simply the above with ?̃?𝑀 replaced by ?̃?𝑚. 
A general formula for the numerator encompassing all three cases is derived in 2.4.2 
Generalization of VAF and MCF Relationship for All Three Cases. Division of the numerator by 
the denominator gives us the VAF, and the likelihood can then be expressed as 
𝐿( 𝑍, 𝑃, ?̃?𝑀, ?̃?𝑚, 𝐻, ?̃?, 𝜏𝐾 | 𝑊
𝑀 , 𝑊𝑚, 𝜀𝑀, 𝜀𝑚, 𝑅, 𝑋, 𝑌)
= ∏ ∏ ∏ {pNorm (𝑊𝑡𝑗
𝑀, (?̃?𝑀 × 𝑃)
𝑡𝑗
, (𝜀𝑡𝑗
𝑀)
2
)
𝑇
𝑡=1
𝑆
𝑠=1
𝑁
𝑗=1
  
              pNorm (𝑊𝑡𝑗
𝑚, (?̃?𝑚 × 𝑃)
𝑡𝑗
, (𝜀𝑡𝑗
𝑚)
2
) pBinomial(𝑉𝐴𝐹𝑠𝑗 , 𝑅𝑠𝑗 , 𝑋𝑠𝑗)} , 
where pNorm(𝑥, 𝜇, 𝜎2) is the likelihood for observing 𝑥 from a Gaussian distribution with 
mean 𝜇 and standard deviation 𝜎, pBinomial(𝑝, 𝑅, 𝑋) is the Binomial likelihood for observing 𝑅 
successes from 𝑋 trials with success probability 𝑝, 𝐻 indicates the phasing of the SNAs with 
overlapping CNAs (whether an SNA precedes a CNA), ?̃? is a vector of the ordering of the SNA-
CNA pair that can be directly obtained from the tree, VAF is derived in 2.4.2 Generalization of 
VAF and MCF Relationship for All Three Cases. 
For cases where nested CNAs are observed, Canopy samples the temporal and spatial 
orders of the CNAs together with the affected SNAs in the phylogenic tree. Resolving overlapping 
and nested CNA events is not trivial, since in real datasets analysis we only see the major and 
minor allelic ratio per region per sample. By overlapping CNAs we are referring to distinct CNA 
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events occurring in separate samples that affect the same genomic region, more specifically, 
overlapping across samples (e.g., CNA event 𝐸1 and 𝐸2 in Figure 2.3b); by nested CNAs, on the 
other hand, we are referring to CNAs that may occur in different samples or within the same 
sample (e.g., CNA event 𝐸2 and 𝐸3 in Figure 2.3b). Canopy can resolve CNA events, overlapping 
or nested, that have representation in the data. For such events, manual inspection of the 
segmentation input is sometimes helpful to identify nested CNAs within the same sample and to 
verify the type (gain, loss, or copy neutral LOH) of each event. 
We use BIC as a model selection method to determine the number of subclones 𝐾 and 
design a Metropolis Hastings algorithm to sample the posterior distribution of the unknowns and 
enumerate all plausible histories in the tree space: 
(i) randomly switch a CNA or SNA to another branch on the tree; 
(ii) randomly select at least two clones and change their clonal frequencies; 
(iii) randomly select a neighborhood for local rearrangement to generate a new tree topology 
(Figure 2.4); 
(iv) randomly select a CNA and sample its major and minor copy number from {0,1,2,3} and 
update ?̃?𝑡𝑘
𝑀 and ?̃?𝑡𝑘
𝑚, 1 ≤ 𝑡 ≤ 𝑇, 1 ≤ 𝑘 ≤ 𝐾; 
(v) for SNA that resides in a CNA (𝑄𝑠 = 1), randomly sample whether the major or the minor 
allele contains the SNA after the copy number change, aka, randomly sample the indicator 
random variable 𝐻𝑠 (1 ≤ 𝑠 ≤ 𝑆). 
For each run, we start with multiple chains from different start points and evaluate convergence 
by likelihood and acceptance rate. Posterior distribution is marginalized after combining different 
chains, burn-in, and thinning. When multiple posterior ‘modes’ exist, Canopy attempts to return all 
phylogenies that the data support and computes the relative confidence interval in each clonal 
history. Quantities that can be marginalized from the posterior distributions are obtained from 
subtree space with trees having the same clonal and mutational compositions. 
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2.2.5 Simulation Studies 
As a simple illustration, we first show how Canopy successfully identifies the subclones and 
recovers the phylogeny for the scenario shown in Figure 2.1 and Figure 2.5, which is a simple 
configuration that is as typical as any other given the level of complexity. We also use this 
example to demonstrate the differences between Canopy and two related methods, PhyloWGS 
and Clomial. To generate suitable input for PhyloWGS, we converted the CNA events to pseudo-
SNA events, since in this toy example we have at our disposal the true clonal proportions as well 
as the true SNA-CNA phasing, and thus simply used these true values as if it were known. Refer 
to 2.4.3 Simulation Setup for details. Canopy, starting with raw CNA estimates and assuming 
unknown phase, returns a tree highly concordant with the ground truth; whereas PhyloWGS, 
even using the true phase and clonal proportions for CNAs, returns a linear tree with incorrectly 
inferred cellular frequencies (Figure 2.5c). We further introduce scenarios where CNAs overlap 
and show that Canopy can successfully handle a fair amount of complexity. As a comparison, 
Clomial (72), which ignores the existence of CNAs, fails to correctly estimate the clonal 
frequencies and infers incorrect tumor purities (Figure 2.5b). Figure 2.5d also explores the effect 
of CNA estimation noise on deconvolution accuracy. 
We then performed simulation studies to explore the effects of various parameters on 
estimation accuracy as well as computation time, and evaluate performance benchmarked 
against existing methods. We use the percentage of wrongly labeled 𝑍 elements (Figure 2.6) and 
the root-mean-square error (RMSE) of the 𝑃 matrix (Figure 2.7) as a measure of the 
deconvolution accuracy and compare Canopy’s results with those returned by Clomial (72). We 
use clustering purity as a measure of clustering quality and compare the pre-clustering results of 
Canopy with those of SciClone (63). We sampled systematically from a comprehensive set of 
possible phylogenies and 𝑃 matrices. More details on simulation setup are in 2.4.3 Simulation 
Setup. 
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We ran simulations with varying number of mutations from two different sequencing 
pipelines: whole-genome sequencing with 𝑑 = 30 (Figure 2.7a) and targeted sequencing with 𝑑 =
500 (Figure 2.7b), where 𝑑 is the mean sequencing depth. The results give a sense of how 
estimation accuracy depends on the number of informative mutations, the number of 
genotypically distinct samples, the sequencing depth, and the number of underlying clones. As 
expected, estimation accuracy increases with the number of genotypically distinct samples, the 
number of informative mutations, and the sequencing depth. Increasing the number of subclones 
makes the estimation problem harder, although this can be compensated for by a larger number 
of mutations. Also, in Figure 2.8, we show that the larger the difference in clonal proportions 
between the samples, the easier the estimation problem. Under all simulated scenarios, Canopy 
is as good as or better than Clomial (72) and SciClone (63) in terms of deconvolution and 
clustering accuracy (Figure 2.6, Figure 2.7). An interesting observation from the simulation 
studies is that while increasing the number of samples drives the estimation error of 𝑍 to zero, the 
benefit of including more mutations diminishes when there is a small number of underlying 
subclones. In this case, only a small high confidence set of informative mutations or mutation 
clusters is sufficient for recovering the underlying tree (Table 2.3); when the number of underlying 
subclones is large, more mutations are needed (Table 2.3). 
We also performed simulations to investigate the effect of the proposed binomial mixture 
clustering method with varying number of mutations and clones. This pre-clustering procedure 
serves as an initialization step in the MCMC sampling, where mutations are first moved along tree 
branches in clusters and then fine-tuned individually in the later rounds. We show that this 
initialization method significantly reduces computation time, offers a way to clean up data by 
including a uniform noise component, and has similar or better deconvolution accuracy (Table 
2.3, Figure 2.9). 
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2.2.6 Application to Transplantable Metastasis Model Derived from MDA-MB-231 
Canopy is applied to a transplantable metastasis model system derived from a heterogeneous 
human breast cancer cell line MDA-MB-231. Cancer cells from the parental line MDA-MB-231 
were engrafted into mouse hosts leading to organ-specific metastasis. Single cell populations 
(SCPs) or mixed cell populations (MCPs) were in vivo selected from either bone or lung 
metastasis and grew into phenotypically stable and metastatically competent cancer cell lines 
(Figure 2.10a, Table 2.4). 
This transplantable model system has been widely used for understanding metastatic 
progression (82-84). Minn et al. (82) identified a ‘poor-prognosis’ gene expression signature for 
distinct metastatic potential by studying patterns of transcriptomic profile. Recently, Jacob et al. 
(83) performed whole-exome sequencing on a metastasis model derived from the same parental 
line MDA-MB-231 and found that in vivo selected highly metastatic cell populations showed little 
genetic divergence from the corresponding parental population. Their results suggest that: (i) 
genetic variations (including oncogenic mutations in BRAFG464V and KRASG13D, validated by 
Sanger sequencing) preexist in the parental line and are enriched with increased metastatic 
capability; (ii) metastatic competence during tumorigenesis can emerge with selection of 
preexisting oncogenic alleles without a need of new mutations (83). 
Here we build a transplantable model from MDA-MB-231, where the parental line as well 
as the SCP and MCP samples are whole-exome sequenced and are used to investigate clonal 
evolution associated with metastatic progression on the DNA level. We only use the parental line 
and the MCP samples to infer metastatic phylogeny, while the SCP samples are included as a 
validation dataset to compare and contrast. Since SCP samples are homogeneous cell 
populations, their integer absolute copy numbers can be inferred by a hidden Markov model 
(HMM). Since we do not have a normal control for MDA-MB-231, the integer absolute copy 
numbers for the SCP samples are used as controls to infer copy number ratios in the MCP 
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samples (Figure 2.11). SNAs and indels are called by the UnifiedGenotyper in the Genome 
Analysis Toolkit (GATK) (85) and are further annotated by ANNOVAR (86). 
In addition to the oncogenic point mutations in BRAF and KRAS reported by Jacob et al. 
(83), our analysis pipeline identified two nonsynonymous mutations in ALPK2 and RYR1 that are 
deleterious by functional annotation. VAFs of the four mutations vary between bone and lung 
metastasis samples: BRAF and KRAS mutations are enriched in the bone samples; ALPK2 
mutation is enriched in the lung samples; RYR1 mutation is additionally acquired by the bone 
samples from the parental line (Figure 2.10b). These four mutations also overlap with six CNAs 
events, with regions in chromosome (chr) 7q and 12 being double ‘hit’ by two non-identical 
overlapping CNA events in separate samples (Figure 2.12). 
The a posteriori most likely phylogenetic tree inferred by Canopy using the parental line 
and the MCP samples only has four subclones guided by BIC (Figure 2.10c) and is shown in 
Figure 2.10d. As expected, our results show that the bone and lung metastatic sublines acquire 
additional mutation from the parental line and form organ-specific subclones that dominate the 
metastasis. All samples, except MCP2287, are almost 100% comprised of cells from a single 
clone. Clone 2 is unique to the lung subline and clone 3 is unique to the brain subline (Figure 
2.10d). MCP2287 partially retains the parental line and is a mixture of two subclones, which, upon 
detailed visual inspection, is supported by the raw SNA and CNA input (Figure 2.10b, Figure 
2.12a-b). For CNAs, Canopy successfully resolves overlapping CNAs with correctly inferred copy 
number states (Figure 2.12); among the SNAs, BRAF, KRAS, and ALPK2 each undergo a 
duplication event that amplifies the mutant allele, with BRAF and KRAS further losing the 
reference allele via a second LOH event (Figure 2.10d) that occurs later in the evolutionary 
process. All sublines share chr 12 duplication, while the bone and lung sublines gain additional 
mutations that mark and/or drive their divergence (Figure 2.10d). 
Canopy’s inferred phylogeny is confirmed by the SCP samples, which we use as 
validation. The two SCP samples derived from the lung metastasis are 100% identical to clone 2, 
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and the two derived from the bone metastasis are 100% identical to clone 3 (Figure 2.10d). 
Similar to Jacob et al. (83), Canopy’s inferred phylogeny shows that amplification of oncogenic 
signals preexisting in the parent cell line (KRAS, BRAF, and ALPK2) leads to higher tumor-
initiating fitness. Nevertheless, in contradiction to the proposed model by Jacob et al. (83) where 
no new mutations are needed, here we report additionally acquired SNA and CNAs as DNA 
signatures that mark and/or drive the divergence between the lung and bone sublines. These 
mutation signatures—chr 18q deletion, RYR1 point mutation, and chr 7q and 12 LOH—can 
indicate breast cancer metastatic potentials and serve as prognostic markers for the development 
of distant metastasis. 
2.2.7 Application to Breast Cancer Patient Xenografts 
We further applied Canopy to a deep-genome sequencing dataset of breast cancer patient 
xenografts from Eirew et al. (57). Xenografts of a patient line were generated by serially 
transplanting breast cancer tissue organoid suspensions into immunodeficient mice (57). Whole-
genome sequencing was performed on the initial engraftment (SA494T) and its subsequent 
propagation of metastatic xenograft (SA494X4). Targeted-amplicon deep sequencing was 
performed to validate somatic SNAs; TITAN (64) was applied to infer CNAs and LOH (57). We 
adopt bivariate clustering and stringent quality control procedures to remove experimental noise 
(Figure 2.13a). Canopy takes as input SNAs from four clusters that are CNA-free, three SNAs 
that overlap with CNAs, and four CNAs (chr1p, 3p, and 19p deletion and chr5q duplication) to 
reconstruct phylogeny. 
 The number of subclones is chosen at 4 by BIC as a criterion for model selection (Figure 
2.13b). The most likely tree returned by Canopy is shown in Figure 2.13c. Clone 2 and clone 3 
(2% and 1% of the starting population, SA494T) undergo a one-copy loss event and additionally 
acquire SNAs in cluster 3, indicating extreme selective engraftment of minor clones (Figure 
2.13c). These two clones are further separated by SNAs in cluster 4 and become dominant in the 
subsequent metastatic xenograft SA494X4 with high prevalence (77% and 23% shown in Figure 
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2.13c). For SNAs that overlap with CNAs, only SNA2 precedes its affecting CNA2 (one-copy loss) 
and has a higher mutational multiplicity after losing the healthy allele. Both SNA1 and SNA3 arise 
after one-copy-loss events, resides in clone 1 only, and thus are present in sample SA494T but 
not in SA494X4. 
 We compared our analysis result to the SNA clustering result achieved by Pyclone (62).  
SNA clusters 1-4 correspond to the four clusters inferred by Pyclone shown in Figure 2.13c, 
which is expected since the SNAs within these clusters are CNA-free and these cell lines are 
expected to have no normal cell contamination (𝐶𝐶𝐹 = 𝑀𝐶𝐹 = 2 × 𝑉𝐴𝐹). While Pyclone outputs 
the clustering of these MCFs, Canopy also infers the evolutionary relationship between the clones 
represented by these clusters. Thus, from this analysis we can be quite confident that the 
mutations in cluster 2 are ancestral to the mutations cluster 4, that is, cells which carry the 
mutations in cluster 4 must also carry the mutations in cluster 2. Also, Pyclone uses CNA-
corrected VAFs of SNAs as input whereas Canopy uses both SNAs and CNAs simultaneously to 
infer tumor phylogeny. This allow us to infer the temporal order of the CNA events in relation to 
the SNA events. For example, we are quite confident that CNAs 1 and 3 are clonal events, while 
CNA 2 and CNA 4 came later affecting separate subclones. 
Canopy’s results are confirmed by single-cell sequencing carried out by Eirew et al. 
(57)—two mutually exclusive sets of mutant alleles from SA494 tumor and passage 4 xenograft 
respectively were identified in addition to a set of shared alleles (57). 
2.2.8 Application to Normal, Primary Tumor, and Relapse Genome of Leukemia Patients 
As proof of principle and to further illustrate our method, we apply Canopy to the longitudinal 
dataset from Ding et al. (54), where whole-genome sequencing was performed on the normal 
tissue, the primary tumor, and the relapse genome of leukemia patients. 1292 and 412 candidate 
somatic SNAs and indels were identified in sample AML43/UPN869586 and AML1/UPN933142 
respectively and were confirmed by deep sequencing (54). CNAs (total copy numbers) were also 
predicted (54). 
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By the weak parsimony assumption and in a similar fashion to Pyclone (62) and SciClone 
(63), we first adopt a binomial mixture clustering method to cluster all the mutations into 
mutational ‘waves’ and give an estimate of the VAF of each cluster (Figure 2.14a). To gain 
robustness against false positives calls, we add a mixture component (shown as pink dots in 
Figure 2.14a), with a small weight, that is uniform on the unit interval. Our clustering results show 
that in both patients, there is a one unique mutation cluster identified in the primary tumor, and 
one found at relapse. Furthermore, all mutation clusters are heterozygous and diploid, except 
mutation cluster 1 (mut1) in AML43, the mutations in which all reside in a copy number neutral 
LOH region from chr 16. The VAFs of the SNAs as well as the absolute copy number of the LOH 
(major copy 2, minor copy 0) are used as input for Canopy to infer phylogenetic trees. 
For this dataset, Canopy returns only one plausible clonal history that can explain the 
observed mutation profiles, shown in Figure 2.14b. We re-parameterize the model to 
accommodate a redistribution event between the two time-points to improve interpretability. The 
tree is observed twice, first at the collection of the primary tumor, and then at the stage of relapse 
malignancy. Through the selection bottleneck that is imposed between the two time-points, 
mutations can arise (e.g., mutation cluster 5 (mut5) shown in red in Figure 2.14b) and clonal 
frequencies (shown in blue in Figure 2.14b) can change—some subclones expand while others 
become extinct or remain dormant. Meaningful quantities can be marginalized from the posterior 
distribution in the tree space. For example, Figure 2.14c shows the posterior distribution of the 
clonal frequencies through the selection bottleneck—a minor clone (clone 3 in AML43 and clone 
4 in AML1) carrying the vast majority (but not all) of the primary tumor mutations survives the 
chemotherapy and becomes dominant at relapse by acquiring additional mutations (mut5 in both 
samples) while the remaining clones diminish (Figure 2.14c). Normal cell fractions are also 
estimated with their posterior distributions shown in the first columns of Figure 2.14c. 
While Ding et al. (54) arrived at this same clonal history manually (a minor clone carrying 
the vast majority of the primary tumor mutations survived and expanded at relapse), we automate 
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the analysis pipeline via Canopy and allow the inclusion of both SNAs and CNAs. Canopy’s 
inferred phylogenies shown in Figure 2.14b, as well as its estimated clonal frequencies and tumor 
purities shown in Figure 2.14c, are concordant with the results and conclusions in Ding et al. (54). 
2.2.9 Application to ten spatially separated samples of ovarian cancer 
We further evaluate Canopy’s performance on a data set with spatial experimental design from 
Bashashati et al. (55). 63 somatic mutations (SNAs and indels) were confirmed by deep amplicon 
resequencing in ten tumor samples from different dissections (4a-4e, right ovary; 4f-4i, left ovary; 
4j, left fallopian tube) of a high-grade serous ovarian cancer patient (Figure 2.15a-b). We keep 
the same assumption as in Bashashati et al. (55) that the 63 SNAs across all samples are 
heterozygous from copy number neutral regions as in the original studies: (i) CNAs weren’t 
profiled in all samples by Affymetrix SNP genotyping arrays; (ii) for the samples with CNA calls, 
only total copy number is available (55). 
BIC for model selection is shown in Figure 2.15c and the number of subclones is chosen 
at 5. Canopy returns posterior trees with one configuration and it is shown in Figure 2.15d. 
Different mutations correspond to rows in the heatmap in Figure 2.15a and are grouped on 
branches with different colors. Specifically, all ten samples share and acquire somatic mutations 
in TP53 and DHX8, along with 13 other mutations in mutation set 2, 3, and 4 shown in light blue, 
green, and orange, indicating a common cell of origin. It is also observed that there is a clear 
separation between the samples from the right ovary and the samples from the left ovary in the 
clonal frequency matrix 𝑃. GLDC, LIG1 as well as the rest mutations in mutation set 5 shown in 
blue drive and/or mark the divergence and thus have the potential to serve as a biomarker to 
indicate whether distal metastasis is formed in ovarian cancer patient. Mutation set 7 in red 
further distinguish case4a from 4b-be and form a unique subclone in case4a. 
Collectively, our results suggest that multiple sublcones migrate from the left ovary to the 
right ovary and that both sample sets are mixtures of different subclones with diversified 
mutational profiles. These mutational profiles from spatially separated samples correlate with 
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spatial distribution due to regional evolutionary selection and reflect different histological 
evolutionary trajectories within a single patient. 
Notably, spatial distribution of the samples in the phylogeny is concordant with the tree 
configuration inferred by Bashashati et al. (55) (Figure 2.15e). Nevertheless, the neighbor joining 
method with Pearson correlation distance metric doesn’t account for many aspects including: (i) 
varying standard errors in the estimates for mutational frequencies due to varying sequencing 
depths; (ii) each spatial sample offers a snapshot of different combinations of subclones and 
therefore they cannot be treated as homogeneous samples at the tips of the tree branches; (iii) 
there is no placement of mutation along the tree; (iv) the inference of branch lengths assumes a 
constant biological clock, which doesn’t hold in cancer genomes. Popic et al. (70) also 
reconstructed a clonal tree (Figure 2.15f) that is highly similar to the one returned by Bashashati 
et al. (55). Somatic mutations arise from the germline (GL) sample and are placed in the 
phylogeny with numbers shown on tree branches. There are three subclones with distinct 
mutational. The proportion of the subclonal admixtures, however, remains unknown with samples 
at tree tips. 
2.3 Discussion 
Intra-tumor heterogeneity contributes to drug resistance and failures of targeted therapies (87). 
To gain a comprehensive understanding of the evolutionary dynamics of tumors, it is important 
not only to determine which alterations drive the progression of a tumor but also to understand 
their relative temporal and spatial order during tumor evolution. Here we propose a novel method, 
Canopy, to assess intra-tumor heterogeneity and infer clonal evolutionary history. The 
distinguishing features of Canopy compared to existing methods are: (i) SNAs and CNAs are 
jointly modeled and overlapping events are phased and temporally ordered; (ii) The SNA input 
can be taken directly from the GATK (85) or MuTect (88) and the CNA input are continuous-
valued allele-specific copy number ratios, which can be directly obtained from allele-specific copy 
number estimation methods (76); (iii) A pre-clustering initialization step for SNAs improves 
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robustness to noise and significantly reduces computation time; (iv) CNA events are allowed to 
be subclonal (66, 67); (v) overlapping and nested CNA events with different breakpoints affecting 
the same region are treated as separate evolutionary events, as illustrated by our analysis of 
MDA-MB-231; (vi) the Bayesian framework reconstructs the phylogeny together with posterior 
confidence assessment, which is useful when the data supports multiple configurations. 
 Despite the fact that Canopy starts with a pre-clustering, an input that contains too many 
false detections can still lead to unreliable phylogeny inference.  Most current CNA and SNA 
detection algorithms still have a high false positive rate, and thus we suggest rigorous quality 
checking of input before a Canopy analysis. As we showed in our simulations, Canopy does not 
require a large set of variant loci to attain precise phylogeny inference; that is, the payoff for 
including multiple variants derived from the same clone quickly diminishes. A Canopy analysis 
should start with manual inspection and visualization of the input data, followed by removing short 
CNAs that may be unreliably called, and utilizing the pre-clustering procedure with a multivariate 
uniform component on SNAs, as illustrated in our analysis of the data from Ding et al. (54) and 
Eirew et al. (57). 
Canopy has been demonstrated on four cancer sequencing datasets of varying study 
design, as well as on extensive simulation data. On a whole-exome study of breast cancer cell 
line MDA-MB-231, Canopy successfully deconvolved the mixed cell sublines, identifying 
subclones which were validated by comparing to single-cell sublines as ground truth. On a whole-
genome sequencing dataset of the breast cancer tumor and its subsequent metastatic xenograft, 
Canopy’s inferred clonal phylogeny is concordant with genomic markers of major clonal genotype 
and is confirmed by single-cell sequencing. On a whole-genome sequencing dataset of the 
primary tumor and relapse genome of a leukemia patient, and on a spatially sampled targeted 
sequencing study of ovarian cancer, Canopy predicted phylogenetic histories in concordance with 
existing knowledge. Finally, through simulations, we explored the effects of various parameters 
on deconvolution accuracy, and evaluate performance with comparison against existing methods. 
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Collectively, Canopy provides a rigorous foundation for statistical inference on repeated 
sequencing data from evolving populations. 
Many factors determine the accuracy of Canopy’s results: higher sequencing depth 
allows for higher sensitivity for detection of rare subclones; more samples and more difference 
between samples in their clonal composition allow for higher accuracy in estimating the 
phylogeny. In particular, the maximum number of subclones that can be reliably inferred depends 
on all of these factors.  As the number of subclones increase, the proportion of cells attributable 
to at least some of the subclones would necessarily decrease, and higher coverage would be 
needed to detect mutations present in those smaller subclones. A survey of recent multi-region 
and multi-timepoint cancer genome sequencing studies shows that, even in scenarios where up 
to 11 bulk samples were analyzed from the same patient, the number of subclones identified was 
typically less than 8 (summarized in Table 2.1).  A similar range for the number of subclones was 
found by single cell sequencing. To increase resolution for rare subclones, deeper sequencing or 
sequencing of a larger number of single cells is needed. 
Most current cancer sequencing studies sequence only one sample from each patient, 
from which it is difficult to deconvolve clonal mixtures. The recent advances in single-cell 
sequencing technologies make possible a different approach to study tissue heterogeneity at 
higher resolution. Nevertheless, reliable simultaneous profiling of copy number and single 
nucleotide mutations by single-cell sequencing is still at infancy. Here, we show that traditional 
bulk sequencing can lead to accurate subclone identification and phylogenetic inference, if only 
the researcher is willing to sequence multiple slices of the tissue. Thus, bulk tissue sequencing 
can play an important part in our understanding of tumor heterogeneity, and in the coming years 
experimental designs that combine bulk tissue sampling and single cell analysis needs to be 
better explored. 
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2.4 Methods 
2.4.1 Allele-Specific Copy Number 
For the 𝑡th (1 ≤ 𝑡 ≤ 𝑇) CNA, we let 𝑁𝑡 be the number of germline heterozygous loci within its 
segment (segmentation carried out by FALCON (76) or FALCON-X). From FALCON’s 
segmentation and phasing outputs, we can get for each tumor-normal pair the read counts of 
major and minor allele in the 𝑗th tumor slice, 𝑀𝑖𝑗 and 𝑚𝑖𝑗, and in the matched normal sample, 𝑀𝑖0 
and 𝑚𝑖0, where 1 ≤ 𝑖 ≤ 𝑁𝑡 is the germline SNP index and 1 ≤ 𝑗 ≤ 𝑁 is the sample index. 
For CNA events that are non-overlapping (Figure 2.3a), we use the germline 
heterozygous loci within each CNA segment to compute major and minor copy number input 
across all samples: 
𝑊𝑡𝑗
𝑀 =
1
𝑁𝑡
∑ (𝑀𝑖𝑗 𝑀𝑖0⁄ )
𝑁𝑡
𝑖=1
, (𝜀𝑡𝑗
𝑀)
2
=
∑ (𝑀𝑖𝑗 𝑀𝑖0⁄ )
2𝑁𝑡
𝑖=1 − 𝑁𝑡(𝑊𝑡𝑗
𝑀)
2
𝑁𝑡(𝑁𝑡 − 1)
; 
𝑊𝑡𝑗
𝑚 =
1
𝑁𝑡
∑ (𝑚𝑖𝑗 𝑚𝑖0⁄ )
𝑁𝑡
𝑖=1
, (𝜀𝑡𝑗
𝑚)
2
=
∑ (𝑚𝑖𝑗 𝑚𝑖0⁄ )
2𝑁𝑡
𝑖=1 − 𝑁𝑡(𝑊𝑡𝑗
𝑚)
2
𝑁𝑡(𝑁𝑡 − 1)
. 
In the above, 𝑊𝑡𝑗
𝑀 , 𝑊𝑡𝑗
𝑚 are the estimates of the major and minor copy numbers, respectively, and 
𝜀𝑡𝑗
𝑀, 𝜀𝑡𝑗
𝑚 can be considered as their standard errors. 
For CNA events that are overlapping or nested (Figure 2.3b), we propose a new 
algorithm that automates the pre-processing of allele-specific copy number for input to Canopy. If 
external ploidy information is available, this can be added as a fixed CNA event (e.g., a genome 
doubling event for tetraploidy). Specifically, we propose a 4-step prioritization algorithm to get the 
major and minor copy numbers for each event, briefly summarized as follows: (i) Merge CNA 
events where both endpoints are close, e.g. within 1 kb of each other; (ii) Identify nested CNA 
events, e.g., a homozygous deletion residing in a one-copy deletion region; (iii) Rank overlapping 
and nested CNA events by a Chi-square score, details below; (iv) Get major and minor copy 
number estimates through a recursive procedure. Now we expand on the details, with an 
illustrative example shown in Figure 2.3. Let 𝐸1, 𝐸2, … , 𝐸𝑇 be the CNA events collected across all 
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samples after the merging step (i), which may contain nested or overlapping events; let 𝜋𝑡
(𝑗)
 (1 ≤
𝜋𝑡
(𝑗)
≤ 𝑇) be the ranking of event 𝑡 (1 ≤ 𝑡 ≤ 𝑇) in sample 𝑗 (1 ≤ 𝑗 ≤ 𝑁) (Figure 2.3c) based on its 
Chi-squared statistic, 
𝑄𝑡𝑗 = (
𝑊𝑡𝑗
𝑀 − 1
𝜀𝑡𝑗
𝑀 )
2
+ (
𝑊𝑡𝑗
𝑚 − 1
𝜀𝑡𝑗
𝑚 )
2
~𝜒2
2, 
with larger Chi-square ranked higher (i.e. smaller 𝜋𝑡
(𝑗)
 value), but with an important caveat 
that nested events always takes precedence over the event that it resides in regardless of their 
Chi-square values, e.g., homozygous deletion event 𝐸3 always has a higher ranking than 
heterozygous deletion 𝐸2 (Figure 2.3c). Another important detail is that, at this point, the input 
values  𝑊𝑀 , 𝑊𝑚, 𝜀𝑀, and 𝜀𝑚 used to compute 𝑄𝑡𝑗 are estimated from segments with shared 
breakpoints across all samples due to the preceding merging step. As a result, in some samples 
certain segments may have a mixture of more than one copy number state if it overlaps with a 
different CNA from another sample, e.g., in Figure 2.3b sample 1 has three copy number states in 
the segment that corresponds to event 𝐸1. These segments won’t have the highest Chi-squared 
values so they should be ranked low, as desired. To get an accurate estimate of major and minor 
copy numbers for overlapping and nested CNAs we adopt the algorithm outlined below, the result 
of which on the illustrative example is also shown in Figure 2.3c. For each sample 𝑗, 
(1) Start with event 𝑡 with the highest ranking: 𝜋𝑡
(𝑗)
= 1, get 𝑊𝑡𝑗
𝑀, 𝑊𝑡𝑗
𝑚 , 𝜀𝑡𝑗
𝑀, and 𝜀𝑡𝑗
𝑚 by taking 
the mean and standard error across all heterozygous loci that reside within this event; 
(2) For event 𝑡: 𝜋𝑡
(𝑗)
> 1, in computing the major and minor copy number input, use segment 
𝐸𝑡 excluding all segments of lower rank, that is, 
𝐸𝑡\ ⋃ 𝐸𝑡′
𝜋
𝑡′
𝑗
<𝜋𝑡
𝑗
. 
2.4.2 Generalization of VAF and MCF Relationship for All Three Cases 
Here we derive a general formula for the numerator encompassing all three cases. We denote 
𝐻 ∈ ℝ𝑆 as a vector of indicator of whether an SNA is from the major or the minor copy of the CNA 
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that affects it and occurs after it. We further define 𝑄 as a vector indicating whether an SNA 
precedes the CNA it resides in, which can be directly obtained from the tree 𝜏𝐾. Let 𝐻 =
[𝐻′, 𝐻′, … , 𝐻′]𝐾 ∈ ℝ
𝑆×𝐾 and ?̃? = [𝑄′, 𝑄′, … , 𝑄′]𝐾 ∈ ℝ
𝑆×𝐾. Then, the numerator for all three cases 
shown in Figure 2.2 can be generalized and division of the numerator by the denominator gives 
us the VAF matrix: 
𝑉𝐴𝐹 =
{𝑍 ∙ (𝑌 × [
𝟙
⋯
?̃?𝑀
])
?̃?
∙ ?̃? + 𝑍 ∙ (𝑌 × [
𝟙
⋯
?̃?𝑚
])
?̃?
∙ (1 − 𝐻)}  × 𝑃
(𝑌 × [
𝟙
⋯
?̃?𝑀
] + 𝑌 × [
𝟙
⋯
?̃?𝑚
]) × 𝑃
∈ ℝ𝑆×𝑁 . 
Note that the exponentiation and division are carried out in an element-wise fashion and that 00 is 
defined to be equal to 1. This generalized matrix representation form to get VAFs of SNAs only 
apply to SNAs that are CNA-free or those that are affected by a single CNA event. For SNAs that 
are affected by more than one CNA event, VAFs are obtained iteratively for each SNA with 
adjustment of the affecting CNA events that are overlapping or nested. 
2.4.3 Simulation Setup 
We firstly generate input data from the true underlying tree with and without overlapping CNAs 
respectively and apply Canopy to reconstruct the phylogeny. For SNAs, the total read depth 
matrix 𝑋 has each of its column sampled from a multinomial distribution  
𝑋:,𝑗~Multinomial (𝑑 × 𝑆,
1
𝑆
, … ,
1
𝑆
), 
where 𝑑 is the mean sequencing depth and 1 ≤ 𝑗 ≤ 𝑁. The mutant read depth matrix 𝑅 is 
sampled from a binomial distribution indexed at 𝑋 with success probabilities 𝑉𝐴𝐹 derived in 2.2.4 
SNA-CNA Phase and Combined Likelihood (numerator divided by denominator). For CNAs, the 
input matrix 𝑊𝑀 and 𝑊𝑚 are sampled from a normal distribution with mean ?̃?𝑀 × 𝑃 and ?̃?𝑚 × 𝑃 
and standard deviation 𝜀𝑀 and 𝜀𝑚 ranging from 0.001 to 0.64 (Figure 2.5d). The matrices 𝑋, 𝑅, 
𝑊𝑀, 𝑊𝑚, 𝜀𝑀, and 𝜀𝑚 are then used as input for Canopy to infer phylogeny with output shown in 
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Figure 2.5a. For Clomial (72), we keep its assumptions and use 𝑋 and 𝑅 as input to infer 
phylogeny with result shown in Figure 2.5b. 
We then separately investigate the effects of the number of mutations, the sequencing 
depth, the number of samples, the number of subclones, and the pre-clustering procedure as an 
initialization step on deconvolution and pre-clustering accuracy and computation time. Without 
loss of generality, we focus on using SNAs to reconstruct phylogeny and compare against two 
existing methods, Clomial (72) and SciClone (63). For each investigation, we control for 
confounding parameters, run 30 simulations in parallel, and integrate results from each run. 
Within each simulation, we run 10 Markov chains with random starts and correspondingly choose 
𝑏𝑖𝑛𝑜𝑚𝑇𝑟𝑦𝑁𝑢𝑚 = 10 for Clomial (72), a parameter specifying the number of random starts for the 
EM algorithm. The true clonal frequency matrix 𝑃 is pre-fixed but varies between different runs 
with a perturbation added to each of its element from a Gaussian distribution with mean 0 and 
standard deviation 0.01. The generated matrix is then scaled so that each element is non-
negative and that the columns sum up to one. We calculate the percentage of wrongly labeled 
elements in 𝑍 (Figure 2.6) and the RMSE of the inferred 𝑃 matrix (Figure 2.7) across all 
simulation runs. 
Number of mutations and sequencing depth 
We start with constructing a true underlying tree with a fixed number of subclones. Various 
numbers of mutations are placed on branches of the tree (except for the leftmost one) with equal 
probabilities and as a result we can get a true genotyping matrix 𝑍. The clonal frequency matrix 𝑃 
is fixed so that we can control for the number of subclones, the number of samples, and the 
clonal compositions. Here we mimic two different sequencing pipelines—whole-genome 
sequencing with 𝑑 = 30 and targeted sequencing with 𝑑 = 500. The input matrix 𝑋 is sampled 
from the multinomial distribution and the mutant read depth matrix 𝑅 is then sampled from a 
binomial distribution  
𝑅~Binomial (𝑋,
1
2
𝑍 × 𝑃). 
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Number of samples 
We evaluate the effect of the number of samples by running parallel simulations with fixed 
number of subclones (𝐾 = 5) and mutation clusters (𝑆 = 7) but varied number of samples, which 
correspond to columns of the clonal frequency matrix 𝑃. Since adding a same sample doesn’t 
guarantee adding additional information for phylogeny reconstruction, we choose and fix the 
elements of the 𝑃 matrix so that the additive summation result is the most distinct in the unit 
space and that different combinations of subclones are present across different samples. We 
further measure the deconvolution difficulty quantitatively from the 𝑃 matrix itself. Specifically, we 
define 𝑞 ∈ ℝ(2𝐾−3)×𝑁 as the summation of the offspring subclonal frequencies at each of the 
(2𝐾 − 3) internal edges across all samples,  
𝑞𝑖𝑗 = ∑ 𝑃𝑠𝑗{𝑠: 𝑠 is descedant of edge 𝑖} (1 ≤ 𝑖 ≤ 2𝐾 − 3, 1 ≤ 𝑗 ≤ 𝑁). 
The statistic that we use to measure the deconvolution difficulty of the the 𝑃 matrix is  
𝑞𝑚𝑖𝑛 = min
{𝑖≠𝑖′}
‖𝑞𝑖 − 𝑞𝑖′‖
2, 
where 𝑞𝑖 = (𝑞𝑖1, 𝑞𝑖2, … , 𝑞𝑖𝑁) (Figure 2.8). 
Number of subclones 
We study the effect of the number of subclones by keeping the 𝑃 matrix the same with varied 
number of rows (3 ≤ 𝐾 ≤ 10). The number of samples is fixed at 3, among which there is the 
greatest distinction of clonal compositions; the number of mutations is set at 𝐾 + 2. In addition to 
measure the accuracy of the inferred 𝑍 and 𝑃 matrix, we also compare Canopy’s pre-clustering 
result against that of SciClone’s (63). We use clustering purity as a measure of clustering quality. 
To compute clustering purity, each cluster is assigned to the class which is most frequent in the 
cluster, and then the accuracy of this assignment is measured by counting the number of 
correctly assigned mutations and dividing by the total number of mutations. We further carry out 
simulations to examine a larger subclone space and to investigate the tradeoff between the 
number of subclones, the sequencing depth, as well as the number of mutations. Running time, 
estimation errors of the 𝑍 and the 𝑃 matrix are recorded (Table 2.3). 
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Binomial mixture clustering 
We investigate the effect of the binomial mixture clustering on computation time and 
deconvolution accuracy. The binomial mixture clustering is carried out as an initialization step to 
guide the MCMC sampling procedure – we firstly move the mutational clusters along the tree 
branches and then fine tune every mutation within each cluster. Simulation is carried out with 
varying number of mutations 𝑁 ∈ {25,50,100,200} along trees with different number of clones 𝐾 ∈
{3,4,5,6} from three samples. The true underlying clonal frequency matrix 𝑃 is the same as is in 
the previous section. Convergence is measured by both the log-likelihood and the acceptance 
rate (Figure 2.9), with running time recorded and estimation errors measured (Table 2.3). 
2.4.4 WES of Transplantable Metastasis Model Derived from MDA-MB-231 
The parental cell line MDA-MB-231 was obtained from the American Type Tissue Collection. Its 
derivative cell lines (both SCPs and MCPs) were described previously (82, 89, 90). Cells were 
grown in high-glucose DMEM medium with 10% fetal bovine serum. Genomic DNA was 
harvested with Purelink genomic DNA kit (Invitrogen). Exome libraries were prepared with 
SureSelect Human All Exon kit (Agilent) and were sequenced on an Illumina Hiseq-2000 
sequencer. The WES data have been deposited in the BioProject database with accession 
number PRJNA315318. 
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Figure 2.1: Tumor phylogeny, observed input, and inferred output of Canopy.  (a) Phylogeny 
of tumor progression as a bifurcating tree with SNAs and CNAs along the branches. Longitudinal 
and/or spatial samples offer different snapshot of subpopulations, represented by tree leaves. 
The lengths of the branches are arbitrary—since without further strong assumptions, we cannot 
infer branch length from this data. (b) Observed VAFs, major copies, and minor copies across 
samples. Matrix 𝑌 indicates whether an SNA resides in a CNA. (c) Matrix decomposition by 
Canopy. Genotyping matrix 𝑍 represents the positions of the SNAs in the phylogeny. ?̃?𝑀 and ?̃?𝑚 
encode major and minor copy number of each clone. 𝐻 specifies SNA-CNA phasing—whether 
SNAs reside in major or minor copies. Clonal frequency matrix 𝑃 is shown as part of (a). 
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Figure 2.2: Three cases of SNA-CNA phase and order. Different phases and orders of CNA 
and the SNA it affects are shown with clonal histories concordant with Figure1. Major and minor 
copies are in blue and red respectively; SNA mutational loci are shown as stars. (a) CNA 
precedes SNA. SNA resides in only one chromosomal copy. (b) CNA and SNA are on two 
separate branches. SNA is unaffected by CNA. (c) SNA precedes CNA. Scenario where major 
copies contain the SNA is shown. SNA4 from Figure 2.1  is unaffected by CNA and is not shown. 
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Figure 2.3: Illustration on generating CNA input for Canopy. Initial segmentation is performed 
by FALCON-X. (a) For CNAs that aren’t overlapping or nested, the segment mean and standard 
error are computed for each segment across all samples (Methods in main manuscript). (b) For 
CNA events that display overlapping/nested structure, a four-step CNA prioritization algorithm 
(Supplementary Methods) is adopted. (c) The ranking of CNA events in each sample and the 
segments that are used to generate allele-specific copy number calls. (d) The underlying tree 
structure for samples and CNA events shown in (b). 
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Figure 2.4: Generating new tree topology by local rearrangement. A neighborhood—an 
internal node that has both a parent and two children—is selected for local rearrangement. Switch 
the sibling with one of the children to generate a new tree topology (91). 
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Figure 2.5: Inferred phylogenies by Canopy, Clomial and PhyloWGS. (a) Canopy successfully 
decomposes all matrices with confidence assessment. (b) Clomial doesn’t utilize somatic CNA 
information and fails to estimate the clonal frequencies with zero normal cell contaminations in all 
three samples. The true quantities are shown in Figure 1. (c) True phylogeny and estimated 
phylogeny by Canopy and PhyloWGS. Canopy returned a tree highly concordant with the ground 
truth whereas PhyloWGS returned a linear tree with incorrectly inferred cellular frequencies. The 
input for this dataset can be found in the Canopy R-package. (d) Higher noise (spiked-in error 
term 𝜀) doesn’t seem to affect Canopy’s estimation of the genotyping matrix Z but leads to higher 
estimation error of the clonal proportion P. The estimation error is taken as the median across ten 
parallel runs. 
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Figure 2.6: Deconvolution accuracy and clustering quality via simulation studies.  Various 
parameters show effects on deconvolution accuracy (measured by the percentage of wrongly 
labeled 𝑍 elements) and pre-clustering quality (measured by the clustering purity). Canopy is 
compared against Clomial and SciClone and is shown to have better performance. (a-b) Whole-
genome sequencing compensates its low sequencing depth with more profiled mutations. (c) 
Increasing sample size helps solve reconstruction ambiguity. (d-e) Number of subclones is 
negatively correlated with deconvolution accuracy and pre-clustering quality. 
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Figure 2.7: Deconvolution accuracy via simulation studies.  Various parameters show effects 
on deconvolution accuracy (measured by RMSE of the 𝑃 matrix). (a-b) Whole-genome 
sequencing compensates the lower sequencing depth with more profiled mutations. (c) Large 
number of samples helps solve reconstruction ambiguity. (d) Number of subclones is negatively 
correlated with deconvolution accuracy. Canopy outperforms Clomial under all settings. 
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Figure 2.8: 𝒒𝒎𝒊𝒏 as a measure of deconvolution difficulty from the clonal frequency matrix 
𝑷.  The larger the 𝑞𝑚𝑖𝑛 is, the more distinct the clonal frequencies at the tree edges are, and thus 
the more difficult the deconvolution problem is. 
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Figure 2.9: Log-likelihood of MCMC sampling with and without pre-clustering step.  
Simulation is carried out with 200 mutations along a five-branch tree using three samples. Ten 
chains shown in different color are randomly started with (a) and without (b) a Binomial mixture 
clustering step. Convergence is measured by both the log-likelihood and the acceptance rate. 
Pre-clustering step significantly reduces computation time with MCMC converging faster. 
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Figure 2.10: Clonal history of transplantable metastasis model MDA-MB-231 with validation 
by SCP samples. (a) Transplantable model system of MDA-MB-231. Parental line is injected into 
mouse models and induces organ-specific metastasis. Sublines are derived from single or 
multiple cell(s) from different metastatic sites. (b) Observed VAFs of somatic SNAs, which reside 
in nested CNAs. Canopy takes both SNA and CNA input. (c) BIC as a model selection method to 
determine the number of subclones. (d) Clonal tree reconstructed by Canopy. Sublines acquire 
additional mutation from the parental line and form organ-specific subclones that dominate the 
metastasis. SCP samples successfully validate the subclones and confirm Canopy’s inferred 
phylogeny. 
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Figure 2.11: CNA inference by HMM. (a) HMM is applied to segment the genome in SCP 
samples and manually corrected by the exonic coverage ratios between two SCPs. B allele 
frequencies (BAFs) are used as input. Deletion/LOH is shown in red, duplication in blue, and copy 
number neutral region in green. Purple line is the log ratio of the segmented total copy numbers, 
overlaid by the corresponding depth of coverage ratio. (b) Using SCP as a normal control, CNAs 
for the MCP sample is called. 
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(d) 
 
Figure 2.12: Canopy’s CNA input to infer phylogeny in the parental cell line and its 
sublines. Six somatic CNAs from four different chromosomes—(a) chr7, (b) chr12, (c) chr18, (d) 
chr19. Chr7 and chr12 are double ‘hit’ by two CNAs; chr18 and chr19 undergo one-copy loss and 
gain respectively. CNA subclonal events result in different allele specific copy number states 
across different samples. The observed B allele frequencies (BAFs), i.e., 𝑊𝑀 (𝑊𝑀 + 𝑊𝑚)⁄  and 
𝑊𝑚 (𝑊𝑀 + 𝑊𝑚)⁄ , are used as input for Canopy to infer the clonal tree. 
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Figure 2.13: Clonal architecture of breast cancer initial engraftment and passage 
xenograftment. Tumor sample SA494T and its subsequent xenograft SA494X4 are whole-
genome sequenced with SNAs validated by deep amplicon resequencing and CNAs inferred by 
TITAN. (a) SNA and CNA input of Canopy. VAFs of four SNA clusters and three CNA-affected 
SNAs are shown in the top panel. Heatmap of observed major and minor copy numbers are 
shown in the bottom panel. (b) BIC as a model selection metric to determine the number of 
subclones. (c) The most likely tree returned by Canopy based on the mutational profiling. 
Extreme selection of minor clones is imposed on engraftment. SA494T and SA494X4 bear two 
mutually exclusive sets of mutations in addition to shared ancestral mutations. (d) Mutation 
clusters inferred by the Pyclone model. 
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Figure 2.14: Clonal history reconstructed from primary tumor and the relapse genome of 
leukemia patients. (a) VAFs of SNAs and indels of the primary tumor and the relapse genome of 
patient AML43 and AML1 are clustered into mutational waves shown in different colors. A mixture 
component with a small weight shown as pink dots is included to gain robustness against false 
positives. CNAs for each mutational cluster are profiled. SNAs and CNAs are used as input for 
Canopy. (b) Plausible phylogenies inferred by Canopy, observed at two time-points. Mutations 
and clonal proportions are shown in red and blue respectively. Both trees support the model that 
a subclone from the primary tumor gains additional mutations and expands at relapse. (c) 
Inference of clonal frequency from the posterior distribution. One subclone survives the 
chemotherapy and becomes dominant. Normal cell contaminations/tumor purities are estimated 
as the first columns. 
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Figure 2.15: Clonal history reconstructed from ten spatially separated samples. Ten ovarian 
cancer tumor samples from different regions (4a-4e, right ovary; 4f-4i, left ovary; 4j, left fallopian 
tube) from case 4 in Bashashati et al. (55) are whole exome sequenced. 63 mutations are 
confirmed by deep amplicon resequencing. (a) Heatmap of mutational profiling across 63 genes, 
10 samples. (b) Anatomical sites of the ten spatially separated samples. (c) BIC as a model 
selection metric to determine the number of subclones. (d) The most likely tree returned by 
Canopy based on the mutational profiling. Mutations in blue are additionally acquired by the right 
ovary samples from the left ovary samples and drive the divergence. Mutations in red further 
distinguish case4a from the rest of the samples from the right ovary.  Each sample offers a 
snapshot of different combinations of the subclones that is correlated with their spatial 
distribution. (e) Tree reconstructed by Bashashati et al. (55) by a nearest neighbor method. (f) 
Tree reconstructed by Popic et al. (70) as an acyclic directed graph. Both methods put samples at 
the tree leaves as homogeneous populations. 
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Table 2.1: Cancer genomic studies by sequencing multiple samples from the same 
patients. Multiple types of cancer were sequenced by different platforms by a longitudinal (multi-
time point) or a spatial experimental (multi-region) design. For bulk-tissue sequencing, 5 to 12 
samples were sequenced from the same individual; for single-cell sequencing, ~100 single cells 
were sequenced. Across all studies, less than 8 cancer clones were identified. NA*: Bashashati et 
al. (55) and Gerlinger et al. (56) constructed phylogenetic tree by neighbour-joining and maximum 
parsimony method and put bulk-tumor samples as tree leaves. 
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Table 2.2: Properties and assumptions of cancer clonal phylogeny reconstruction 
methods.  Y, yes; N, no; N/A, not applicable. 
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Table 2.3: Running time and estimation error with and without pre-clustering step.  
Simulation is carried out with varying number of mutations 𝑁 ∈ {25,50,100,200} along trees with 
different number of branches 𝐾 ∈ {3,4,5,6} from three samples. Canopy is run with and without a 
Binomial clustering procedure (C for clustering and NC for non-clustering) as an initialization step 
for MCMC. Convergence is measured by both the log-likelihood and the acceptance rate. Run 
time is measured in seconds; estimation error of the genotyping matrix 𝑍 is measured as the 
percentage of wrongly labeled elements; RMSE is used to measure the estimation error of the 
clonal proportion matrix 𝑃. Pre-clustering step significantly reduces computation time for larger 
number of mutations and results in comparable or smaller estimation errors. 
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 Cell type Metastatic outcome 
MDA-MB-231 Parental line - 
1833 Mixed-cell subline (MCP) Bone 
2287 Mixed-cell subline (MCP) Bone 
SCP2 Single-cell subline (SCP) Bone 
SCP46 Single-cell subline (SCP) Bone 
1834 Mixed-cell subline (MCP) Lung 
3481 Mixed-cell subline (MCP) Lung 
SCP3 Single-cell subline (SCP) Lung 
SCP43 Single-cell subline (SCP) Lung 
Table 2.4: Metastatic outcomes and cell population types of MDA-MB-231 and its sublines. 
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CHAPTER 3   
MODELING ALLELE-SPECIFIC GENE EXPRESSION BY SINGLE-CELL RNA SEQUENCING 
3.1 Introduction 
In diploid organisms, two copies of each autosomal gene are available for transcription, and 
differences in gene expression level between the two alleles are widespread in tissues (92-98). 
Allele-specific expression (ASE), in its extreme, is found in genomic imprinting, where the allele 
from one parent is uniformly silenced across cells, and in random X-chromosome inactivation, 
where one of the two X-chromosomes in females is randomly silenced. During the last decade, 
using single-nucleotide polymorphism (SNP)-sensitive microarrays and bulk RNA sequencing 
(RNA-seq), more subtle expression differences between the two alleles were found, mostly in the 
form of allelic imbalance of varying magnitudes in mean expression across cells (99-102). In 
some cases such expression differences between alleles can lead to phenotypic consequences 
and result in disease (94, 103-105). These studies, though revelatory, were at the bulk tissue 
level, where one could only observe average expression across a possibly heterogeneous 
mixture of cells. 
Recent developments in single-cell RNA sequencing (scRNA-seq) have made possible 
the better characterization of the nature of allelic differences in gene expression across individual 
cells (97, 106, 107). For example, recent scRNA-seq studies estimated that 12-24% of the 
expressed genes are monoallelically expressed  during mouse preimplantation development (93) 
and that 76.4% of the heterozygous loci across all cells express only one allele (108). These 
ongoing efforts have improved our understanding of gene regulation and enriched our vocabulary 
in describing gene expression at the allelic level with single-cell resolution. 
Despite this rapid progress, much of the potential offered by scRNA-seq data remains 
untapped. ASE, in the setting of bulk RNA-seq data, is usually quantified by comparing the mean 
expression level of the two alleles. However, due to the inherent stochasticity of gene expression 
across cells, the characterization of ASE using scRNA-seq data should look beyond mean 
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expression. A fundamental property of gene expression is transcriptional bursting, in which 
transcription from DNA to RNA occurs in bursts, depending on whether the gene’s promoter is 
activated (Figure 3.1A) (109, 110). Transcriptional bursting is a widespread phenomenon that has 
been observed across many species including bacteria (111), yeast (112), Drosophila embryos 
(113), and mammalian cells (114, 115), and is one of the primary sources of expression variability 
in single cells. Figure 3.1B illustrates the expression across time of the two alleles of a gene. 
Under the assumption of ergodicity, each cell in a scRNA-seq sample pool is at a different time in 
this process, implying that for each allele, some cells might be in the transcriptional “ON” state, 
whereas other cells are in the “OFF” state. While in the “ON” state, the magnitude and length of 
the burst can also vary across cells, further complicating analysis. For each expressed 
heterozygous site, a scRNA-seq experiment gives us the bivariate distribution of the expression 
of its two alleles across cells, allowing us to compare the alleles not only in their mean, but also in 
their distribution.  In this paper, we will use scRNA-seq data to characterize transcriptional 
bursting in an allele-specific manner and detect genes with allelic differences in the parameters of 
this process. 
Kim and Marioni (116) first studied bursting kinetics of stochastic gene expression from 
scRNA-seq data, using a Beta-Poisson model and estimated the kinetic parameters via a Gibbs 
sampler. In this early attempt, they assumed shared bursting kinetics between the two alleles and 
modeled total expression of a gene instead of allele-specific expression. Current scRNA-seq 
protocols often introduce substantial technical noise (Figure 3.2) (117-121), and these noise (e.g., 
gene dropouts, amplification and sequencing bias) are largely ignored in Kim and Marioni (116) 
and another recent scRNA-seq study Borel et al. (108), where, in particular, gene dropout may 
have led to overestimation of the pervasiveness of monoallelic expression (ME). Realizing this, 
Kim et al. (122) incorporated measurements of technical noise from external spike-in molecules 
into the identification of stochastic ASE (defined as excessive variability in allelic ratios among 
cells), and concluded that more than 80% of stochastic ASE in mouse embryonic stem cells are 
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due to scRNA-seq technical noise. Kim et al.’s analysis was restricted to the identification of 
random monoallelic expression (RME) and did not consider more general patterns of ASE such 
as allele-specific transcriptional bursting. 
ScRNA-seq also enables us to quantify the degree of dependence between the 
expressions of the two alleles. A previous RNA fluorescence in situ hybridization (FISH) 
experiment fluorescently labeled 20 genes in an allele-specific manner and showed that there 
was no significant deviation from independent bursting between the two alleles (123). A recent 
scRNA-seq study of mouse cells through embryonic development (93) produced similar 
conclusions on the genome-wide level: They modeled transcript loss by splitting each cell’s lysate 
into two fractions of equal volume and controlling for false discoveries by diluting bulk RNA down 
to single-cell level. Their results suggest that on the genome-wide scale, assuming both alleles 
share the same bursting kinetics, the two alleles of most genes burst independently. Deviation 
from the theoretical curve in Deng et al. (93) for independent bursting with shared allele-specific 
kinetics, however, can be due to not only dependent bursting, but also differential bursting 
kinetics. 
In this paper, we develop SCALE (Single-Cell ALlelic Expression) (124), a systematic 
statistical framework to study ASE in single cells by examining allele-specific transcriptional 
bursting kinetics. Our main goal is to detect and characterize differences between the two alleles 
in their expression distribution across cells. As a by-product, we will also quantify the degree of 
dependence between the expressions of the two alleles. SCALE is comprised of three steps. 
First, an empirical Bayes method determines, for each gene, whether it is silent, monoallelically 
expressed, or biallelically expressed, based on its allele-specific counts across cells (Figure 
3.1C). Next, for genes determined to be biallelic bursty (i.e., both alleles have zero expression 
level in some but not all cells), a Poisson-Beta hierarchical model is used to estimate allele-
specific transcriptional kinetics while accounting for technical noise and cell size differences. 
Finally, resampling-based testing procedures are developed to detect allelic differences in 
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transcriptional burst size or burst frequency, and identify genes whose alleles exhibit non-
independent transcription. 
In silico simulations are conducted to investigate estimation accuracy and testing power. 
The stringency of model assumptions, and the robustness of the proposed procedures to the 
violation of these assumptions, will be discussed as they are introduced. Using SCALE, we re-
analyze the scRNA-seq data for 122 mouse blastocyst cells (93) and 104 human fibroblast cells 
(108). The mouse blastocyst study initially found abundant RME generated by independent and 
stochastic allelic transcription (93); the human fibroblast study reported that 76.4% of the 
heterozygous loci displayed patterns of ME (108). Through proper modeling of technical noise, 
our re-analysis of these two datasets brings forth new insights: While for 90% of the bursty genes, 
there are no significant deviations from the assumption of independent allelic bursting and shared 
bursting kinetics, the remaining bursty genes show differential burst frequency by a cis-effect 
and/or non-independent bursting with an enrichment in coordinated bursting. Collectively, we 
present a genome-wide approach to systematically analyze expression variation in an allele-
specific manner with single-cell resolution. SCALE is an open-source R package available at 
https://github.com/yuchaojiang/SCALE. 
3.2 Results 
Here we propose SCALE, a statistical framework for systematic characterization of ASE using 
data generated from scRNA-seq experiments. Our approach allows us to profile allele-specific 
bursting kinetics while accounting for technical variability and cell size difference. For genes that 
are classified as biallelic bursty through a Bayes categorization framework, we further examine 
whether transcription of the paternal and maternal alleles are independent, and whether there are 
any kinetic differences, as represented by bursty frequency and burst size, between the two 
alleles. Our results on the re-analysis of Deng et al. (93) and Borel et al. (108) provide insights 
into the extent of differences, coordination, and repulsion between alleles in transcriptional 
bursting. 
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Figure 3.3 shows an overview of the analysis pipeline of SCALE. We start with allele-
specific read counts of endogenous RNAs across all profiled single cells. An empirical Bayes 
method is adopted to classify expression of genes into monoallelic, biallelic, and silent states 
based on ASE data across cells. SCALE then estimates allele-specific transcriptional bursting 
parameters via a hierarchical Poisson-Beta model, while adjusting for technical variabilities and 
cell size differences. Statistical testing procedures are then performed to identify genes whose 
two alleles have different bursting parameters or burst non-independently. We describe each of 
these steps in turn. 
3.2.1 Gene Classification by ASE Data across Cells 
SCALE first determines for each gene whether its expression is silent, paternal/maternal 
monoallelic, or biallelic. Figure 3.1C outlines this categorization scheme. Briefly, for each gene, 
each cell is assigned to one of four categories corresponding to scenarios where both alleles are 
off (∅), only A allele is expressed (𝐴), only B allele is expressed (𝐵), and both alleles are 
expressed (𝐴𝐵). An expectation-maximization (EM) algorithm is implemented for parameter 
estimation. This classification accounts for both sequencing depth variation and sequencing 
errors. The assignment of the gene is then determined based on the posterior assignments of all 
cells. For example, if all cells are assigned to {∅}, the gene is silent; if all cells are assigned to 
either {∅} or {𝐴}, the gene has ME of the A allele; if all cells are assigned to either {∅} or {𝐵}, the 
gene has ME of the B allele; if both A and B allele are expressed in the cell pool, then the gene is 
biallelically expressed. Refer to 3.4.2 Empirical Bayes Method for Gene Categorization for 
detailed statistical method and the EM algorithm. 
Through simulation studies (under section 3.2.8 Assessment of estimation accuracy and 
testing power), we show that bursting parameters can only be stably estimated for bursty genes, 
that is, genes that are silent in a non-zero proportion of cells. Therefore, for biallelic bursty genes, 
allele-specific transcriptional kinetics are modeled through a Poisson-Beta distribution with 
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adjustment of technical noise. For silent, monoallelically expressed, or constitutively expressed 
genes, there is no way nor need to estimate bursting kinetics for both alleles. 
3.2.2 Allele-Specific Transcriptional Bursting 
When studying ASE in single cells, it is critical to consider transcriptional bursting due to its 
pervasiveness in various organisms (111-115). We adopt a Poisson-Beta hierarchical model to 
quantify allele-specific transcriptional kinetics while accounting for dropout events and 
amplification and sequencing bias. Here, we start by reviewing the relevant literature with regard 
to transcriptional bursting at the single-cell level. 
 A two-state model for gene transcription is shown in Figure 3.1A, where genes switch 
between the “ON” and “OFF” states with activation and deactivation rates 𝑘𝑜𝑛 and 𝑘𝑜𝑓𝑓. When the 
gene is at the “ON” state, DNA is transcribed into RNA at rate 𝑠 while RNA decays at rate 𝑑. A 
Poisson-Beta stochastic model was firstly proposed by Kepler and Elston (125): 
𝑌~Poisson(𝑠𝑝), 
𝑝~Beta(𝑘𝑜𝑛, 𝑘𝑜𝑓𝑓), 
where 𝑌 is the number of mRNA molecules and 𝑝 is the fraction of time that the gene spends in 
the active state, the latter having mean 𝑘𝑜𝑛 (𝑘𝑜𝑛 + 𝑘𝑜𝑓𝑓)⁄ .  Under this model, 1 𝑘𝑜𝑛⁄  and 1 𝑘𝑜𝑓𝑓⁄  
are the average waiting times in the inactive and active states, respectively. Burst size, defined as 
the average number of synthesized mRNA per burst episode, is given by 𝑠 𝑘𝑜𝑓𝑓⁄ , and burst 
frequency is given by 𝑘𝑜𝑛. Kepler and Elston (125) gave detailed analytic solutions via differential 
equations. Raj et al. (114) offered empirical support for this model via single-molecule FISH 
experiment on reporter genes. Since the kinetic parameters are measured in units of time and 
only the stationary distribution is assumed to be observed (e.g., when cells are killed for 
sequencing and fixed for FISH experiment), the rate of decay 𝑑 is set to one (106). This is 
equivalent to having three kinetic parameters {𝑠, 𝑘𝑜𝑛 , 𝑘𝑜𝑓𝑓}, each normalized by the decay rate 𝑑. 
Kim and Marioni (116) applied this Poisson-Beta model to total gene-level transcript counts from 
scRNA-seq data of mouse embryonic stem cells. While they found that the inferred kinetic 
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parameters are correlated with RNA polymerase II occupancy and histone modification (116), 
they didn’t address the issue of technical noise, especially the dropout events, introduced by 
scRNA-seq. Failure of accounting for gene dropouts may lead to biased estimation of bursting 
kinetics. 
Furthermore, since the transitions between active and inactive states occur separately for 
the two alleles, when allele-specific expression data are available, it seems more appropriate to 
model transcriptional bursting in an allele-specific manner. The fact that transcriptional bursting 
occurs independently for the two alleles has been supported by empirical evidence: Case studies 
based on imaging methods have suggested that the two alleles of genes are transcribed in an 
independent fashion (126, 127); using scRNA-seq data, Deng et al. (93) showed that the two 
alleles of most genes tend to fire independently with the assumption that both alleles share the 
same set of kinetic parameters. These findings, although limited in scale or relying on strong 
assumptions, emphasize the need to study transcriptional bursting in an allele-specific manner. 
3.2.3 Technical Noise in scRNA-seq and Other Complicating Factors 
Figure 3.2 outlines the major steps of the scRNA-seq protocols and the sources of bias that are 
introduced during library preparation and sequencing. After the cells are captured and lysed, 
exogenous spike-ins are added as internal controls, which have fixed and known concentration 
and can thus be used to convert the number of sequenced transcripts into actual abundances. 
During the reverse transcription, pre-amplification, and library preparation steps, lowly expressed 
transcripts might be lost, in which case they will not be detected during sequencing. This leads to 
the so-called “dropout” events. Since spike-ins undergo the same experimental procedure as 
endogenous RNAs in a cell, amplification and sequencing bias can be captured and estimated 
through the spike-in molecules. Here we adopt the statistical model in TASC (Toolkit for Analysis 
of Single Cell data, unpublished), which explicitly models the technical noise through spike-ins. 
TASC’s model is based on the key observation that the probability of a gene being a “dropout” 
depends on its true expression in the cell, with lowly expressed gene more likely to drop out. 
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Specifically, let 𝑄𝑐𝑔 and 𝑌𝑐𝑔 be, respectively, the observed and true expression level of gene 𝑔 in 
cell 𝑐. The hierarchical mixture model used to model dropout, amplification and sequencing bias 
is: 
𝑄𝑐𝑔  ~ 𝑍𝑐𝑔Poisson (𝛼𝑐(𝑌𝑐𝑔)
𝛽𝑐
) , 
𝑍𝑐𝑔 ~ Bernoulli(𝜋𝑐𝑔), 
𝜋𝑐𝑔 = expit(𝜅𝑐 + 𝜏𝑐log (𝑌𝑐𝑔)), 
where 𝑍𝑐𝑔 is a Bernoulli random variable indicating that gene 𝑔 is detected in cell 𝑐, that is, a 
dropout event has not occurred. The success probability 𝜋𝑐𝑔 = 𝑃(𝑍𝑐𝑔 = 1) depends on log (𝑌𝑐𝑔), 
the logarithm of the true underlying expression. Cell-specific parameters 𝛼𝑐 models the capture 
and sequencing efficiency; 𝛽𝑐 models the amplification bias; 𝜅𝑐 and 𝜏𝑐 characterize whether a 
transcript is successfully captured in the library. This model will later be used to adjust for 
technical noise in allele-specific expression. 
 As input to SCALE, we recommend scRNA-seq data from cells of the same type. 
Unwanted heterogeneity, however, still persists as the cells may differ in size or may be in 
different phases of the cell cycle. Through a series of single-cell FISH experiments, Padovan-
Merhar et al. (128) showed how gene transcription depends on these exogenous factors: burst 
size is independent of cell cycle but is kept proportional to cell size by a trans mechanism; burst 
frequency is independent of cell size but is reduced approximately by half, through a cis 
mechanism, between G1 and G2 phase to compensate for the doubling of DNA content. Figure 
3.4 gives an illustration on how burst size and burst frequency change with cell size and cell cycle 
phase. Note that, while the burst frequency from each DNA copy is halved when the amount of 
DNA is doubled, the total burst frequency remains roughly constant through the cell cycle. Thus, 
SCALE adjusts for variation in cell size through modulation of burst size, and does not adjust for 
variation in cell cycle phase. Details will be given below. 
There are multiple ways to measure cell size. Padovan-Merhar et al. (128) proposed using the 
expression level of GAPDH as a cell size marker. When spike-ins are available, we use the ratio 
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of the total number of endogenous RNA reads over the total number of spike-in reads as a 
measure (Figure 3.4) of the total RNA volume, which was shown to be a good proxy for cell size 
(119). SCALE allows the user to input the cell sizes 𝜙𝑐, if these are available through other 
means. 
3.2.4 Modeling Transcriptional Bursting with Adjustment of Technical and Cell-Size 
Variation 
We are now ready to formulate the allele-specific bursting model for scRNA-seq data.  For genes 
that are categorized as biallelic bursty (with proportion of cells expressing each allele between 
5% and 95% from the Bayes framework), SCALE proceeds to estimate the allele-specific bursting 
parameters using a hierarchical model: 
𝑌𝑐𝑔
𝐴  ~ Poisson(𝜙𝑐𝑠𝑔
𝐴𝑝𝑐𝑔
𝐴 )        𝑌𝑐𝑔
𝐵  ~ Poisson(𝜙𝑐𝑠𝑔
𝐵𝑝𝑐𝑔
𝐵 )  
𝑝𝑐𝑔
𝐴  ~ Beta(𝑘𝑜𝑛,𝑔
𝐴 , 𝑘𝑜𝑓𝑓,𝑔
𝐴 )       𝑝𝑐𝑔
𝐵  ~ Beta(𝑘𝑜𝑛,𝑔
𝐵 , 𝑘𝑜𝑓𝑓,𝑔
𝐵 ),  
where 𝑌𝑐𝑔
𝐴  and 𝑌𝑐𝑔
𝐵  are the true allele-specific expressions for gene 𝑔 in cell 𝑐. The two alleles of 
each gene are modeled by separate Poisson-Beta distributions with kinetic parameters that are 
gene- and allele-specific. These two Poisson-Beta distributions share the same cell size factor 𝜙𝑐, 
which affects burst size. The true allele-specific expressions 𝑌𝑐𝑔
𝐴  and 𝑌𝑐𝑔
𝐵  are not directly 
observable. The observed allele-specific read counts 𝑄𝑐𝑔
𝐴  and 𝑄𝑐𝑔
𝐵  are confounded with technical 
noise, and follow the Poisson mixture model outlined in the previous section: 
𝑄𝑐𝑔
𝐴  ~ 𝑍𝑐𝑔
𝐴 Poisson (𝛼𝑐(𝑌𝑐𝑔
𝐴 )
𝛽𝑐
)        𝑄𝑐𝑔
𝐵  ~ 𝑍𝑐𝑔
𝐵 Poisson (𝛼𝑐(𝑌𝑐𝑔
𝐵 )
𝛽𝑐
) 
𝑍𝑐𝑔
𝐴  ~ Bernoulli(𝜋𝑐𝑔
𝐴 )                          𝑍𝑐𝑔
𝐵  ~ Bernoulli(𝜋𝑐𝑔
𝐵 ) 
𝜋𝑐𝑔
𝐴 = expit(𝜅𝑐 + 𝜏𝑐log (𝑌𝑐𝑔
𝐴 ))          𝜋𝑐𝑔
𝐵 = expit(𝜅𝑐 + 𝜏𝑐log (𝑌𝑐𝑔
𝐵 )). 
How to generate input to SCALE for both endogenous RNAs and exogenous spike-ins is 
included in 3.4.1 Input for Endogenous RNAs and Exogenous Spike-ins. For parameter 
estimation, we developed a new “histogram-repiling” method to obtain the distribution of 𝑌𝑐𝑔 from 
the observed distribution of 𝑄𝑐𝑔. The bursting parameters are then derived from the distribution of 
 
99 
 
𝑌𝑐𝑔 by moment estimators. Standard errors and confidence intervals of the parameters are 
obtained using nonparametric bootstrap. 
3.2.5 Hypothesis Testing 
For biallelic bursty genes, we use nonparametric Bootstrap to test the null hypothesis that the 
burst frequency and burst size of the two alleles are the same (𝑘𝑜𝑛
𝐴 = 𝑘𝑜𝑛
𝐵 , 𝑠𝐴 𝑘𝑜𝑓𝑓
𝐴⁄ = 𝑠𝐵 𝑘𝑜𝑓𝑓
𝐵⁄ ) 
against the alternative hypothesis that either or both parameters differ between alleles. For each 
gene, we also perform chi-square test to determine if the transcription of the two alleles are 
independent by comparing the observed proportions of cells from the gene categorization 
framework against the expected proportions under independence. For genes where the 
proportion of cells expressing both alleles is significantly higher than expected, we define their 
bursting as coordinated; for genes where the proportion of cells expressing only one allele is 
significantly higher than expected, we define their bursting as repulsed (Figure 3.3). We adopt 
false discovery rate (FDR) to adjust for multiple comparisons. Details of the testing procedures 
are outlined in 3.4.4 Hypothesis Testing Framework. 
3.2.6 Analysis of scRNA-seq Dataset of Mouse Cells during Preimplantation Development 
We re-analyze the scRNA-seq dataset of mouse blastocyst cells dissociated from in vivo F1 
embryos (CAST/female x C57/male) from Deng et al. (93). Transcriptomic profiles of each 
individual cell was generated using the Smart-seq (129) protocol. For 22,958 genes, reads per 
kilo base per million reads (RPKM) and total number of read counts across all cells are available. 
Parental allele-specific read counts are also available at heterozygous loci.  Principal component 
analysis (PCA) was performed on cells from oocyte to blastocyst stages of mouse 
preimplantation development and showed that the first three principal components well separate 
the early-stage cells from the blastocyst cells. The cluster of early-, mid-, and late-blastocyst cells 
are combined to gain sufficient sample size. In discussion, we give further insights on the 
potential effects of cell subtype confounding. Quality control (QC) procedure was adopted to 
remove outliers in library size, mean and standard deviation of allelic read counts/proportions. We 
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apply SCALE to this dataset of 122 mouse blastocyst cells, with a focus on addressing the issue 
of technical variability and modeling of transcriptional bursting. 
Eight exogenous RNAs with known serial dilutions are added in late blastocyst cells and 
are used to estimate the technical-noise associated parameters (Figure 3.5A). We apply the 
Bayes gene classification framework to these cells to get the genome-wide distribution of gene 
categories. Specifically, out of the 22,958 genes profiled across all cells, ~43% are biallelically 
expressed (~33% of the total are biallelic bursty and ~10% of the total are biallelic non-bursty), 
~7% are monoallelically expressed, and ~50% are silent. Our empirical Bayes categorization 
results show that, on the genome-wide scale, the two alleles of most biallelic bursty genes share 
the same bursting kinetics and burst independently (Figure 3.6A), as has been reported by Deng 
et al. (93). 
For the 7,486 genes that are categorized as biallelic bursty, we apply SCALE to identify 
genes whose alleles have different bursting kinetic parameters by the Bootstrap-based 
hypothesis tests as previously described.  After FDR control, we identify 425 genes whose two 
alleles have significant differential burst frequency (Figure 3.7A) and 2 genes whose two alleles 
have significant differential burst size (Figure 3.7B). Figure 3.8 shows the allelic read counts of a 
gene that has differential burst frequency (Btf3l4) and a gene that has differential burst size 
(Fdps).  The two genes with significant differential allelic burst size, namely, gene Fdps and 
Atp6ap2, are also significant in having differential burst frequency between the two alleles. 𝑃-
values from differential burst frequency testing have a spike below the significance level after 
FDR control (Figure 3.7A), while those from differential burst size testing are roughly uniformly 
distributed (Figure 3.7B). 
At the whole genome level, these results show that allelic differences in the expression of 
bursty genes during embryo development is achieved through differential modulation of burst 
frequency rather than burst size. This seems to agree with intuition, since allelic differences must 
be caused by factors that act in cis to regulate gene expression, and cis factors are likely to 
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change burst frequency by affecting promoter accessibility (128, 130-132). On the contrary, while 
it is plausible for cis factors to affect allelic burst size through, for example, the efficiency of RNA 
Polymerase II recruitment or the speed of elongation, the few known cases of burst size 
modulation are controlled in trans (128). Furthermore, previous studies have shown that the 
kinetic parameter that varies the most – along the cell cycle (128), between different genes (133), 
between different growth conditions (134), or under regulation by a transcription factor (135) – is 
the probabilistic rate of switching to the active state 𝑘𝑜𝑛, while the rates of gene inactivation 𝑘𝑜𝑓𝑓 
and of transcription 𝑠 vary much less. 
Our analysis includes 107 male cells (XAY) and 15 female cells (XAXB) and this allows us 
to use those bursty X-chromosome genes as positive controls. As a result of this gender mixture, 
there are more cells expressing the maternal XA allele compared to the paternal XB allele. As 
shown in Figure 3.7, SCALE successfully detects these bursty X-chromosome genes with 
significant difference in allelic burst frequency but not in allelic burst size. If we only keep the 107 
male cells, these X-chromosome genes are correctly categorized as monoallelically expressed – 
the bursting kinetics for the paternal XB allele are not estimable – and in this case there is no 
longer a cluster of significant X-chromosome genes separated from the autosomal genes (Figure 
3.9). 
For biallelic bursty genes, we also used a simple Binomial test to determine if the mean 
allelic coverage across cells is biased towards either allele. This is comparable to existing tests of 
allelic imbalance in bulk tissue, although the total coverage across cells in this dataset is much 
higher than standard bulk tissue RNA-seq data. After multiple hypothesis testing correction, we 
identify 417 genes with significant allelic imbalance, out of which 238 overlap with the significant 
genes from the testing of differential bursting kinetics (Figure 3.10A). Inspection of the estimated 
bursting kinetic parameters in Figure 3.10A shows that, when the burst size and burst frequency 
of the two alleles change in the same direction (e.g., gene Gprc5a in Figure 3.10B), testing of 
allelic imbalance can detect more significant genes with higher power. This is not unexpected – a 
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small insignificant increase in burst size adds on top of an insignificant increase in burst 
frequency resulting in a significant increase in overall expression levels between the two alleles. 
However, for genes in red in the top left and bottom right quadrants of Figure 3.10A, the test for 
differential bursting kinetics detects more genes than the allelic imbalance test. This is due to the 
fact that when burst size and burst frequency change in opposite directions (e.g., gene Dhrs7 in 
Figure 3.10B), their effects cancel out when looking at the mean expression. Furthermore, even 
when the burst size does not change, if the change in burst frequency is small, by using a more 
specific model SCALE has higher power to detect it as compared to an analysis based on mean 
allelic imbalance. Overall, the allelic imbalance test and differential bursting test report 
overlapping but substantially different set of genes, with each test having its benefits. Compared 
to the allelic imbalance test, SCALE gives more detailed characterization of the nature of the 
difference by attributing the change in mean expression to a change in the burst frequency and/or 
burst size. 
It is also noticeable that in Figure 3.10A the vertical axis, ∆𝑓𝑟𝑒𝑞, has a 50% wider range 
than the horizontal axis, ∆𝑠𝑖𝑧𝑒. Therefore, while it is visually not obvious from this scatter plot, 
there are much more genes with large absolute ∆𝑓𝑟𝑒𝑞 than with large absolute ∆𝑠𝑖𝑧𝑒. Although 
the standard errors of these estimated differences are not reflected in the plot, given our testing 
results, those genes with large estimated differences in ∆𝑠𝑖𝑧𝑒 also have large standard errors in 
their estimates, which is further confirmed via simulations. 
Further chi-squared test of the null hypothesis of independence (Figure 3.8C) shows that 
there are 424 genes whose two alleles fire in a significantly non-independent fashion. We find 
that all significant genes have higher proportions of cells expressing both alleles than expected, 
indicating coordinated expression between the two alleles. In this dataset, there are no significant 
genes with repulsed bursting between the two alleles. Repulsed bursting, in the extreme case 
where at most one allele is expressed in any cell, is also referred to as stochastic ME (122). Our 
testing results indicate that, in mouse embryo development, all cases of stochastic ME (i.e., 
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repulsion between the two alleles) can be explained by independent and infrequent stochastic 
bursting. The burst synchronization in the 424 significant genes is not unexpected and is possibly 
due to a shared trans factor between the two alleles (e.g., co-activation of both alleles by a 
shared enhancer). This result is concordant with the findings from a mouse embryonic stem cell 
scRNA-seq study by Kim et al. (122), which reported that the two alleles of a gene show 
correlated allelic expression across cells more often than expected by chance, potentially 
suggesting regulation by extrinsic factors (122). We further discuss the sharing of such extrinsic 
factors under the context of cell population admixtures in Discussion. 
In summary, our results by SCALE suggest that: (i) The two alleles from 10% of the 
bursty genes show either significant deviations from independent firing or significant differences 
in bursting kinetic parameters, (ii) For genes whose alleles differ in their bursting kinetic 
parameters, the difference is found mostly in the burst frequency instead of the burst size, (iii) For 
genes whose alleles violate independence, their expression tends to be coordinated. 
3.2.7 Analysis of scRNA-seq Dataset of Human Fibroblast Cells 
To further examine our findings in a dataset without potential confounding of cell type admixtures, 
we apply SCALE to a scRNA-seq dataset of 104 cells from female human newborn primary 
fibroblast culture from Borel et al. (108). The cells were captured by Fluidigm C1 with 22 PCR 
cycles and were sequenced with on average 36 million reads (100 bp, paired end) per cell. Bulk-
tissue whole genome sequencing was performed on two different lanes with 26-fold coverage on 
average and was used to identify heterozygous loci in coding regions. After QC procedures, 9016 
heterozygous loci from 9016 genes were identified (if multiple loci coexist in the same gene, we 
pick the one with the highest mean depth of coverage). At each locus, we use SAMtools (36) 
mpileup to obtain allelic read counts in each single cell from scRNA-seq, which are further used 
as input for SCALE. 92 ERCC synthesized RNAs were added in the lysis buffer of 12 fibroblast 
cells with a final dilution of 1:40000. The true concentrations and the observed number of reads 
for all spike-ins are used as baselines to estimate technical variability (Figure 3.5B). 
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We apply the gene categorization framework by SCALE and find that out of the 9016 
genes, the proportions of monoallelically expressed, biallelically expressed, and silent genes are 
11.5%, 45.7%, and 42.8%, respectively. For the 2277 genes that are categorized as biallelic 
bursty, we estimate their allele-specific bursting kinetic parameters and find that the correlations 
between the estimated burst frequency and burst size between the two alleles are 0.859 and 
0.692 (Figure 3.11). We then carry out hypothesis testing on differential allelic bursting kinetics. 
After FDR correction, we identified 26 genes with significant differential burst frequency between 
the two alleles (Figure 3.11A) and one gene Nfx1 with significantly differential burst size between 
the two alleles, which is also significant in burst frequency testing (Figure 3.11B). We further carry 
out testing of non-independent bursting between the two alleles and identify 35 significant genes 
after FDR correction (Figure 3.6B). Out of the 35 significant genes, 27 showed patterns of 
coordinated bursting while the rest 8 showed repulsed patterns. 
3.2.8 Assessment of estimation accuracy and testing power 
First, we investigate the accuracy of the moment estimators for the bursting parameters under 
four different scenarios in the Poisson-Beta transcription model: (i) small 𝑘𝑜𝑛 and small 𝑘𝑜𝑓𝑓 , 
which we call bursty and leads to relatively few transitions between the “ON” and “OFF” state with 
a bimodal mRNA distribution across cells (Figure 3.12A); (ii) large 𝑘𝑜𝑛 and small 𝑘𝑜𝑓𝑓, which 
leads to long durations in the “ON” state and resembling constitutive expression with the mRNA 
having  a Poisson-like distribution (Figure 3.12B); (iii) small 𝑘𝑜𝑛 and large 𝑘𝑜𝑓𝑓, which leads to 
most cells being silent (Figure 3.12C); (iv) and large 𝑘𝑜𝑛 and large 𝑘𝑜𝑓𝑓, which leads to 
constitutive expression (Figure 3.12D). 
We generate simulated data for 100 cells from the four cases above and start with no 
technical noise or cell size confounding. Within each case, we vary 𝑘𝑜𝑛, 𝑘𝑜𝑓𝑓, and 𝑠 and use 
relative absolute error |?̂? − 𝜃| 𝜃⁄  as a measurement of accuracy (Figure 3.13). Our results show 
that genes with large 𝑘𝑜𝑛  and small 𝑘𝑜𝑓𝑓 (shown as the black curves in Figure 3.13) have the 
largest estimation errors of the bursting parameters. Statistically it is hard to distinguish these 
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constitutively expressed genes from genes with large 𝑘𝑜𝑛 and large 𝑘𝑜𝑓𝑓 and thus the kinetic 
parameters in this case cannot be accurately estimated, which has been previously reported 
(116, 136). Furthermore, the estimation errors are large for genes with small 𝑘𝑜𝑛, large 𝑘𝑜𝑓𝑓, and 
small 𝑠 (shown as red curves in Figure 3.13) due to lack of cells with nonzero expression. The 
standard errors and confidence intervals of the estimated kinetics from bootstrap resampling 
further confirm the underperformance for the above two classes (Table 3.1). This emphasizes the 
need to adopt the Bayes categorization framework as a first step so that kinetic parameters are 
stably estimated only for genes whose both alleles are bursty. For genes whose alleles are 
perpetually silent or constitutively expressed across cells, there is no good method, nor any need, 
to estimate their bursting parameters. 
Importantly, we see that the estimation bias in transcription rate 𝑠 and deactivation rate 
𝑘𝑜𝑓𝑓 cancel – over/under estimation of 𝑠 is compensated by over/under estimation of 𝑘𝑜𝑓𝑓 – and 
as a consequence the burst size 𝑠 𝑘𝑜𝑓𝑓⁄  can be more stably estimated than either parameter 
alone, especially when 𝑘𝑜𝑛 ≪ 𝑘𝑜𝑓𝑓 (shown as red curves in Figure 3.13). This is further confirmed 
by empirical results that allelic burst size has much higher correlation (0.746 from the mouse 
blastocyst dataset and 0.692 from the human fibroblast dataset) than allelic transcription and 
deactivation rate (0.464 and 0.265 for mouse blastocyst, and 0.458 and 0.33 for human 
fibroblast) (Figure 3.14).  For this reason, all of our results on real data are based on 𝑠 𝑘𝑜𝑓𝑓⁄  and 
we do not consider 𝑠 and 𝑘𝑜𝑓𝑓 separately. 
We further carry out power analysis on the testing of differential burst frequency and 
burst size between the two alleles. The null hypothesis is both alleles sharing the same bursting 
kinetics (𝑘𝑜𝑛
𝐴 = 𝑘𝑜𝑛
𝐵 = 0.2, 𝑘𝑜𝑓𝑓
𝐴 = 𝑘𝑜𝑓𝑓
𝐵 = 0.2, 𝑠𝐴 = 𝑠𝐵 = 50), while the alternative hypotheses with 
differential burst frequency or burst size are shown in the legends in Figure 3.15. The detailed 
setup of the simulation procedures are as follows. (i) Simulate the true allele-specific read counts 
𝑌𝐴 and 𝑌𝐵 across 100 cells from the Poisson-Beta model under the alternative hypothesis. 
Technical noise is then added based on the noise model described earlier with technical noise 
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parameters {𝛼, 𝛽, 𝜅, 𝜏} estimated from the mouse blastocyst cell dataset. (ii) Apply SCALE to the 
observed expression level 𝑄𝐴 and 𝑄𝐵, which returns 𝑝-value for testing differential burst size or 
burst frequency. If the 𝑝-value is less than the significance level, we reject the null hypothesis. (iii) 
Repeat (i) and (ii) 𝑁 times with the power estimated as 
Number of 𝑝−values ≤0.05 
𝑁
. Our results indicate 
that the testing of burst frequency and burst size have similar power overall with relatively 
reduced power if the difference in allelic burst size is due to difference in the deactivation rate 
𝑘𝑜𝑓𝑓. 
We then simulate allele-specific counts from the full model including technical noise as 
well as variations in cell size with the ground truth 𝑘𝑜𝑛
𝐴 = 𝑘𝑜𝑛
𝐵 = 𝑘𝑜𝑓𝑓
𝐴 = 𝑘𝑜𝑓𝑓
𝐵 = 0.2, 𝑠𝐴 = 𝑠𝐵 = 100 
(bursty with small activation and deactivation rate). For parameters quantifying the degree of 
technical noise, we use the estimates from the mouse blastocyst cells (Figure 3.5A) as well as 
the human fibroblast cells (Figure 3.5B). Cell sizes are simulated from a normal distribution with 
mean 0 and standard deviation 0.1 and 0.01. We run SCALE under four different settings: (i) in its 
default setting, (ii) without accounting for cell size, (iii) without adjusting for technical variability, 
(iv) not in an allele-specific fashion but using total coverage as input. Each is repeated 5000 times 
with a sample size of 100 and 400 cells, respectively. Relative estimation errors of burst size and 
burst frequency are summarized across all simulation runs. Our results show that SCALE in its 
default setting has the smallest estimation errors for both burst size and burst frequency (Figure 
3.16, Figure 3.17). Not surprisingly, cell size has larger effect on burst size estimation than burst 
frequency estimation, while technical variability leads to biased estimation of both burst frequency 
and burst size. The estimates taking total expression instead of ASE as input are completely off. 
Furthermore, the estimation accuracy improved as the number of cells increased. These results 
indicate the necessity to profile transcriptional kinetics in an allele-specific fashion with 
adjustment of technical variability and cell size. 
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3.3 Discussion 
We propose SCALE, a statistical framework to study ASE using scRNA-seq data. The input data 
to SCALE are allele-specific read counts at heterozygous loci across all cells. In the two datasets 
that we analyzed, we use the F1 mouse crossing and the bulk-tissue sequencing to profile the 
true heterozygous loci. When these are not available, scRNA-seq itself can be used to retrieve 
allele-specific expression and more specifically haplotype, as illustrated in Edsgard et al. (137). 
SCALE estimates parameters that characterize allele-specific transcriptional bursting, after 
accounting for technical biases in scRNA-seq and size differences between cells. This allows us 
to detect genes that exhibit allelic differences in burst frequency and burst size, and genes whose 
alleles show coordinated or repulsed bursting patterns. Differences in mean expression between 
the two alleles have long been observed in bulk RNA-seq. By scRNA-seq, we now move beyond 
the mean and characterize the difference in expression distributions between the two alleles, 
specifically in terms of their transcriptional bursting parameters. 
Transcriptional bursting is a fundamental property of gene expression, yet its global 
patterns in the genome has not been well characterized, and most studies consider bursting at 
the gene level by ignoring the allelic origin of transcription. In this paper, we reanalyzed the Deng 
et al. (93) and Borel et al. (108) data. We confirmed the findings from Levesque and Raj (123) 
and Deng et al. (93) that for most genes across the genome there is no sufficient evidence 
against the assumption of independent bursting with shared bursting kinetics between the two 
alleles. For genes where significant deviations are observed, SCALE allows us to attribute the 
deviation to differential bursting kinetics and/or non-independent bursting between the two alleles. 
More specifically, for genes that are transcribed in a “bursty” fashion, we compared the 
burst frequency and burst size, between their two alleles. For both scRNA-seq datasets, we 
identify significant number of genes whose allele-specific burstings differ in the burst frequency 
but not in the burst size. Our findings provide evidence that burst frequency, which represents the 
rate of gene activation, is modified in cis, and that burst size, which represents the ratio of 
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transcription rate to gene inactivation rate, is less likely to be modulated in cis. Although our 
testing framework may have slightly reduced power in detecting differential deactivation rate 
(Figure 3.15), the regulation in burst size can either result from a global trans factor or extrinsic 
factors that acts upon both alleles. Similar findings have been previously reported, from different 
perspectives and on different scales, using various technologies, platforms, and model organisms 
(122, 128, 133-135). 
It is worth noting that the estimated bursting parameters by SCALE are normalized by the 
decay rate, where the inverse 1 𝑑⁄  denotes the average life time of an mRNA molecule. Here we 
implicitly make the assumptions that for each allele, the gene-specific decay rates (𝑑𝑔
𝐴 and 𝑑𝑔
𝐵) 
are constant, and thus the estimated allelic burst frequencies are the ratio of true burst frequency 
over decay rate (that is 𝑘𝑜𝑛,𝑔
𝐴 𝑑𝑔
𝐴⁄  and 𝑘𝑜𝑛,𝑔
𝐵 𝑑𝑔
𝐵⁄ ). The decay rates, however, cancel out in the 
numerator and denominator in the allelic burst sizes, 𝑠𝑔
𝐴 𝑘𝑜𝑓𝑓,𝑔
𝐴⁄  and 𝑠𝑔
𝐵 𝑘𝑜𝑓𝑓,𝑔
𝐵⁄ . Therefore, the 
differences that we observe in the allelic burst frequencies can also potentially be due to 
differential decay rates between the two alleles, which has been previously reported to be 
regulated by microRNAs (138). 
It is also important to note that 44% of the genes found to be significant for differential 
burst frequency are not significant in the allelic imbalance test based on mean expression across 
cells. This suggests that expression quantitative trait loci (eQTL) affecting gene expression 
through modulation of bursting kinetics is likely to escape detection in existing eQTL studies by 
bulk sequencing, especially when burst size and burst frequency change in different directions. 
This is further underscored by the study of Wills et al. (139), which measured the expression of 
92 genes affected by Wnt signaling in 1,440 single cells from 15 individuals, and then correlated 
SNPs with various gene-expression phenotypes. They found bursting kinetics as characterized by 
burst size and burst frequency to be heritable, thus suggesting the existence of bursting-QTLs. 
Taken together, these results should further motivate more large scale genome-wide studies to 
systematically characterize the impact of eQTLs on various aspects of transcriptional bursting. 
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Kim et al. (122) described a statistical framework to quantify the extent of stochastic ASE 
in scRNA-seq data by using of spike-ins, where stochastic ASE is defined as excessive variability 
in the ratio of the expression level of the paternal (or maternal) allele between cells after 
controlling for mean allelic expression levels. While they attributed 18% of the stochastic ASE to 
biological variability, they did not examine what biological factors lead to these stochastic ASE. In 
this paper, we attribute the observed stochastic ASE to difference in allelic bursting kinetics. By 
studying bursting kinetics in an allele-specific manner, we can compare the transcriptional 
differences between the two alleles at a finer scale. 
Kim and Marioni (116) described a procedure to estimate bursting kinetic parameters 
using scRNA-seq data. Our method differs from Kim and Marioni (116) in several ways. First, our 
model is an allele-specific model that infers kinetic parameters for each allele separately, thus 
allowing comparisons between alleles. Second, we infer kinetic parameters based on the 
distribution of “true expression” rather than the distribution of observed expression. We are able 
to do this through the use of a simple and novel deconvolution approach, which allows us to 
eliminate the impact of technical noise when making inference on the kinetic parameters. 
Appropriate modeling of technical noise, in particular, gene dropouts, is critical in this context, as 
failing to do so could lead to the overestimation of 𝑘𝑜𝑓𝑓. Third, we employ a gene categorization 
procedure prior to fitting the bursting model. This is important because the bursting parameters 
can only be reliably estimated for genes that have sufficient expression and that are bursty. 
As a by-product, SCALE also allows us to rigorously test, for scRNA-seq data, whether 
the paternal and maternal alleles of a gene are independently expressed. In both scRNA-seq 
datasets we analyzed, we identified more genes whose allele-specific burstings are in a 
coordinated fashion than those in a repulsed fashion. The tendency towards coordination is not 
surprising, since the two alleles of a gene share the same nuclear environment and thus the 
same ensemble of transcription factors. We are aware that this degree of coordination can also 
arise from the mixture of non-homogeneous cell populations, e.g., different lineages of cells 
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during mouse embryonic development, as we combine the early-, mid-, and late-blastocyst cells 
to gain a large enough sample size. While it is possible that this might lead to false positives in 
identifying coordinated bursting events, it will result in a decrease in power for the testing of 
differential bursting kinetics. Given the amount of stochasticity that is observed in the allele-
specific expression data, how to define cell sub-types and how to quantify between-cell 
heterogeneity need further investigation. 
3.4 Methods 
3.4.1 Input for Endogenous RNAs and Exogenous Spike-ins 
For endogenous RNAs, SCALE takes as input the observed allele-specific read counts at 
heterozygous locus 𝑄𝑐𝑔
𝐴  and 𝑄𝑐𝑔
𝐵 , with adjustment by library size factor:  
𝜂𝑐 = median
𝑔
𝑄𝑐𝑔
𝐴 + 𝑄𝑐𝑔
𝐵
[∏ (𝑄𝑐∗𝑔
𝐴 + 𝑄𝑐∗𝑔
𝐵 )𝐶𝑐∗=1 ]
1/𝐶
. 
In addition, for spike-ins, SCALE takes as input the true concentrations of the spike-in molecules, 
the lengths of the molecules, as well as the depths of coverage for each spike-in sequence 
across all cells. The true concentration of each spike-in molecule is calculated according to the 
known concentration (denoted as 𝐶 attomoles/uL) and the dilution factor (x40000): 
𝐶 × 10−18 moles/uL × 6.02214 × 1023mole−1 (Avogadro constant)
40000 (dilution factor)
. 
The observed number of reads for each spike-in is calculated by adjusting for the library size 
factor, the read length, and the length of the spike-in RNA. The bioinformatic pipeline to generate 
the input for SCALE can be found at https://github.com/yuchaojiang/SCALE. 
3.4.2 Empirical Bayes Method for Gene Categorization 
We propose an empirical Bayes method that categorizes gene expressions across cells into 
silent, monoallelic, biallelic states based on their ASE data. Without loss of generality, we focus 
on one gene here with the goal of determining the most likely gene category based on its ASE 
pattern. Let 𝑛𝑐
𝐴 and 𝑛𝑐
𝐵 be the allele-specific read counts in cell 𝑐 for allele A and B, respectively. 
For each cell, there are four different categories based on its ASE – {∅, 𝐴, 𝐵, 𝐴𝐵} corresponding to 
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scenarios where both alleles are off, only A allele is expressed, only B allele is expressed, and 
both alleles are expressed, respectively. Let 𝑘 ∈ {1,2,3,4} represent this cell-specific category. 
The log-likelihood for the gene across all cells can be written as: 
log(ℒ(Θ|𝑛𝐴, 𝑛𝐵)) = log ∏ 𝑓(𝑛𝑐
𝐴, 𝑛𝑐
𝐵|Θ)
𝑐
= ∑ log [∑ 𝜑𝑘𝑓𝑘(𝑛𝑐
𝐴, 𝑛𝑐
𝐵|𝜖, 𝑎, 𝑏)
4
𝑘=1
]
𝑐
, 
where the parameters are Θ = {𝜑1, … , 𝜑4, 𝜖, 𝑎, 𝑏} with ∑ 𝜑𝑘
4
𝑘=1 = 1 and each 𝑓𝑘 is a density 
function parameterized by 𝜖, 𝑎, 𝑏. 𝜖 is the per-base sequencing error rate, and 𝑎 and 𝑏 are hyper-
parameters for a Beta distribution, where 𝜃𝑐~Beta(𝑎, 𝑏) corresponds to the relative expression of 
A allele when both alleles are expressed. It is easy to show that  
𝑓1(𝑛𝑐
𝐴 , 𝑛𝑐
𝐵|𝜖, 𝑎, 𝑏) ∝ 𝜖𝑛𝑐
𝐴+𝑛𝑐
𝐵
, 
𝑓2(𝑛𝑐
𝐴, 𝑛𝑐
𝐵|𝜖, 𝑎, 𝑏) ∝ (1 − 𝜖)𝑛𝑐
𝐴
𝜖𝑛𝑐
𝐵
, 
𝑓3(𝑛𝑐
𝐴, 𝑛𝑐
𝐵|𝜖, 𝑎, 𝑏) ∝ 𝜖𝑛𝑐
𝐴
(1 − 𝜖)𝑛𝑐
𝐵
, 
𝑓4(𝑛𝑐
𝐴, 𝑛𝑐
𝐵|𝜖, 𝑎, 𝑏) ∝ ∫ [𝜃𝑐(1 − 𝜖) + (1 − 𝜃𝑐)𝜖]
𝑛𝑐
𝐴
[𝜃𝑐𝜖 + (1 − 𝜃𝑐)(1 − 𝜖)]
𝑛𝑐
𝐵 𝜃𝑐
𝑎−1(1 − 𝜃𝑐)
𝑏−1
𝐵(𝑎, 𝑏)
𝑑𝜃𝑐
1
0
. 
𝜖 can be estimated using sex chromosome mismatching or be prefixed at the default value, 
0.001. We require 𝑎 = 𝑏 ≥ 3 in the prior on 𝜃𝑐 so that the AB state is distinguishable from the A 
and B states. This is a reasonable assumption in that most genes have balanced ASE on 
average and the use of Beta distribution allows variability of allelic ratio across cells. We adopt an 
EM algorithm for estimation, with 𝑍 being the missing variables: 
𝑍𝑐𝑘 = {
1
0
    if cell 𝑐 belongs to category 𝑘
    otherwise                                     
. 
The complete-data log-likelihood is given as 
log(ℒ(Θ|𝑛𝐴, 𝑛𝐵 , 𝑍)) = log [∑ ∏ 𝑓𝑘(𝑛𝑐
𝐴 , 𝑛𝑐
𝐵|𝜖, 𝑎, 𝑏)𝑍𝑐𝑘𝜑𝑘
𝑍𝑐𝑘
4
𝑘=1𝑐
] 
log(ℒ(Θ|𝑛𝐴, 𝑛𝐵 , 𝑍)) = ∑ ∑ 𝑍𝑐𝑘log (𝜑𝑘)
4
𝑘=1𝑐
+ ∑ ∑ 𝑍𝑐𝑘log [𝑓𝑘(𝑛𝑐
𝐴, 𝑛𝑐
𝐵|𝜖, 𝑎, 𝑏)]
4
𝑘=1𝑐
. 
For each cell, we assign the state that has the maximum posterior probability and only keep a cell 
if its maximum posterior probability is greater than 0.8. Let 𝑁∅, 𝑁𝐴, 𝑁𝐵, and 𝑁𝐴𝐵 be the number of 
cells in state {∅}, {𝐴}, {𝐵}, and {𝐴𝐵}, respectively. We then assign a gene to be: (i) silent if 𝑁𝐴 =
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𝑁𝐵 = 𝑁𝐴𝐵 = 0; (ii) A-allele monoallelic if 𝑁𝐴 > 0, 𝑁𝐵 = 𝑁𝐴𝐵 = 0; (iii) B-allele monoallelic if 𝑁𝐵 >
0, 𝑁𝐴 = 𝑁𝐴𝐵 = 0; (iv) biallelic otherwise (more specifically, biallelic bursty if 0.05 ≤
(𝑁𝐴 + 𝑁𝐴𝐵) (𝑁∅ + 𝑁𝐴 + 𝑁𝐵 + 𝑁𝐴𝐵)⁄ ≤ 0.95 and 0.05 ≤ (𝑁𝐵 + 𝑁𝐴𝐵) (𝑁∅ + 𝑁𝐴 + 𝑁𝐵 + 𝑁𝐴𝐵)⁄ ≤ 0.95). 
3.4.3 Parameter Estimation for Poisson-Beta Hierarchical Model 
Since exogenous spike-ins are added in a fixed amount and don’t undergo transcriptional 
bursting, they can be used to directly estimate the technical-variability-associated parameters 
{𝛼, 𝛽, 𝜅, 𝜏} that are shared across all cells from the same sequencing batch. Specifically, we use 
non-zero read counts to estimate 𝛼 and 𝛽 through log-linear regression: 
𝑄𝑐𝑔  ~ Poisson (𝛼(𝑌𝑐𝑔)
𝛽
), 
where 𝑄𝑐𝑔 > 0, capture and sequencing efficiencies are confounded in 𝛼 and amplification bias is 
modeled by 𝛽. We then use the Nelder-Mead simplex algorithm to jointly optimize 𝜅 and 𝜏, which 
models the probability of non-dropout, using the likelihood function: 
log (ℒ(𝜅, 𝜏|𝑄, 𝑌, ?̂?, ?̂?)) = ∏ ∏ log {pPoisson (𝑄𝑐𝑔 , ?̂?(𝑌𝑐𝑔)
?̂?
)
𝑔𝑐
expit(𝜅 + 𝜏log𝑌𝑐𝑔) + 
                                                                         (1 − expit(𝜅 + 𝜏log𝑌𝑐𝑔)) 𝟙(𝑄𝑐𝑔 = 0)}, 
where  pPoisson(𝑥, 𝑦) specifies the Poisson likelihood of getting 𝑥 from a Poisson distribution with 
mean 𝑦. This log-likelihood function together with the estimated parameters decomposes the zero 
read counts (𝑄𝑐𝑔 = 0) into being from the dropout events or from being sampled as zero from the 
Poisson sampling during sequencing. 
 The allele-specific kinetic parameters are estimated via the moment estimator methods, 
which is more computational efficient than the Gibbs sampler method adopted by Kim and 
Marioni (116). For each gene, the distribution moments of the A allele given true expression 
levels 𝑌𝑐
𝐴 and 𝑌𝑐
𝐵 are: 
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    𝑚1
𝐴 ≡
𝐸[∑ 𝑌𝑐
𝐴
𝑐 ]
∑ 𝜙𝑐𝑐
=
𝑘𝑜𝑛
𝐴 𝑠𝐴
𝑘𝑜𝑛
𝐴 +𝑘𝑜𝑓𝑓
𝐴  
    𝑚2
𝐴 ≡
𝐸[∑ 𝑌𝑐
𝐴
𝑐 (𝑌𝑐
𝐴−1)]
∑ 𝜙𝑐
2
𝑐
=
𝑘𝑜𝑛
𝐴 (𝑘𝑜𝑛
𝐴 +1)(𝑠𝐴)
2
(𝑘𝑜𝑛
𝐴 +𝑘𝑜𝑓𝑓
𝐴 )(𝑘𝑜𝑛
𝐴 +𝑘𝑜𝑓𝑓
𝐴 +1)
 
    𝑚3
𝐴 ≡
𝐸[∑ 𝑌𝑐
𝐴
𝑐 (𝑌𝑐
𝐴−1)(𝑌𝑐
𝐴−2)]
∑ 𝜙𝑐
3
𝑐
=
𝑘𝑜𝑛
𝐴 (𝑘𝑜𝑛
𝐴 +1)(𝑘𝑜𝑛
𝐴 +2)(𝑠𝐴)
3
(𝑘𝑜𝑛
𝐴 +𝑘𝑜𝑓𝑓
𝐴 )(𝑘𝑜𝑛
𝐴 +𝑘𝑜𝑓𝑓
𝐴 +1)(𝑘𝑜𝑛
𝐴 +𝑘𝑜𝑓𝑓
𝐴 +2)
. 
Solving this system of three equations, we have: 
?̂?𝑜𝑛
𝐴 =
−2(−𝑚1
𝐴(𝑚2
𝐴)2 + (𝑚1
𝐴)2𝑚3
𝐴)
−𝑚1
𝐴(𝑚2
𝐴)2 + 2(𝑚1
𝐴)2𝑚3
𝐴 − 𝑚2
𝐴𝑚3
𝐴 
?̂?𝑜𝑓𝑓
𝐴 =
2((𝑚1
𝐴)2 − 𝑚2
𝐴)(𝑚1
𝐴𝑚2
𝐴 − 𝑚3
𝐴)(𝑚1
𝐴𝑚3
𝐴 − (𝑚2
𝐴)2)
((𝑚1
𝐴)2𝑚2
𝐴 − 2(𝑚2
𝐴)2 + 𝑚1
𝐴𝑚3
𝐴)(2(𝑚1
𝐴)2𝑚3
𝐴 − 𝑚1
𝐴(𝑚2
𝐴)2 − 𝑚2
𝐴𝑚3
𝐴)
 
?̂?𝐴 =
−𝑚1
𝐴(𝑚2
𝐴)2 + 2(𝑚1
𝐴)2𝑚3
𝐴 − 𝑚2
𝐴𝑚3
𝐴
(𝑚1
𝐴)2𝑚2
𝐴 − 2(𝑚2
𝐴)2 + 𝑚1
𝐴𝑚3
𝐴 . 
Substituting A with B we get the kinetic parameters for the B allele. To get the sample moments, 
we propose a novel histogram repiling method that gives the sample distribution and sample 
moment estimates of the true expression from the distribution of the observed expression (Figure 
3.18). Specifically, for each gene we denote 𝑐(𝑄) as the number of cells with observed 
expression 𝑄 and 𝑛(𝑌) as the number of cells with the corresponding true expression 𝑌. 𝑐(𝑄) 
follows a Binomial distribution indexed at 𝑛(𝑌) with probability of no dropout: 
𝑐(𝑄) ~ Binomial(𝑛(𝑌), expit(?̂? + ?̂? log 𝑌)). 
Then, 
?̂?(𝑌) =
𝑐(𝑄)
expit(?̂? + ?̂? log 𝑌)
=
𝑐(𝑄)
expit (?̂? +
?̂?
?̂?
log
𝑄
?̂?
)
. 
These moment estimates of the kinetic parameters are sometimes negative as is pointed out by 
Kim and Marioni (116). By in silico simulation studies, we investigate the estimation accuracy and 
robustness under different settings. 
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3.4.4 Hypothesis Testing Framework 
We carry out a nonparametric bootstrap hypothesis testing procedure with the null hypothesis 
that the two alleles of a gene share the same kinetic parameters. The procedures are as follow. 
(i) For gene 𝑔, let {𝑄1𝑔
𝐴 , 𝑄2𝑔
𝐴 , … , 𝑄𝑛𝑔
𝐴 } and {𝑄1𝑔
𝐵 , 𝑄2𝑔
𝐵 , … , 𝑄𝑛𝑔
𝐵 } be the observed allele-specific read 
counts. Estimate allele-specific kinetic parameters with adjustment of technical variability: 
?̂?𝐴 = {?̂?𝑜𝑛,𝑔
𝐴 , ?̂?𝑜𝑓𝑓,𝑔
𝐴 , ?̂?𝑔
𝐴};  ?̂?𝐵 = {?̂?𝑜𝑛,𝑔
𝐵 , ?̂?𝑜𝑓𝑓,𝑔
𝐵 , ?̂?𝑔
𝐵}. 
(ii) Combine the 2𝑛 observed allelic measurements and draw samples of size 2𝑛 from the 
combined pool with replacement. Assign the first 𝑛 with their corresponding cell sizes to allele 
A as {𝑄1𝑔
𝐴∗, 𝑄2𝑔
𝐴∗, … , 𝑄𝑛𝑔
𝐴∗}, the next 𝑛 to allele B {𝑄1𝑔
𝐵∗, 𝑄2𝑔
𝐵∗, … , 𝑄𝑛𝑔
𝐵∗}. Estimate kinetic parameters 
with adjustment of technical variability from the bootstrap samples: 
𝜃𝐴∗ = {𝑘𝑜𝑛,𝑔
𝐴∗ , 𝑘𝑜𝑓𝑓,𝑔
𝐴∗ , 𝑠𝑔
𝐴∗};  𝜃𝐵∗ = {𝑘𝑜𝑛,𝑔
𝐵∗ , 𝑘𝑜𝑓𝑓,𝑔
𝐵∗ , 𝑠𝑔
𝐵∗}. 
Iterate this 𝑁 times. 
(iii) Compute the p-values: 
𝑝 =
∑ 𝟙(|𝜃𝐴∗ − 𝜃𝐵∗| ≥ |?̂?𝐴 − ?̂?𝐵|)
𝑁
. 
We adopt a Binomial test of allelic imbalance with the null hypothesis that the allelic ratio of the 
mean expression across all cells is 0.5. Chi-square test of independence is further performed to 
test whether the two alleles of a gene fire independently. The observed number of cells is from 
the direct output of the Bayes gene categorization framework. For all hypothesis testing, we adopt 
FDR to adjust for multiple comparisons. 
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Figure 3.1: Allele-specific transcriptional bursting and gene categorization by single-cell 
ASE. (A) Transcription from DNA to RNA occurs in bursts, where genes switch between the “ON” 
and the “OFF” states. 𝑘𝑜𝑛, 𝑘𝑜𝑓𝑓, 𝑠, and 𝑑 are activation, deactivation, transcription, and mRNA 
decay rate in the kinetic model respectively. (B) Transcriptional bursting of the two alleles of a 
gene give rise to cells expressing neither, one, or both alleles of a gene, sampled as vertical 
snapshots along the time axis. Partially adapted from Reinius and Sandberg (97). (C) Empirical 
Bayes framework that categorizes each gene as silent, monoallelic and biallelic (biallelic bursty, 
one-allele constitutive, and both-alleles constitutive) based on ASE data with single-cell 
resolution. 
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Figure 3.2: scRNA-seq protocol and technical variability. Dropouts and amplification and 
sequencing bias are introduced in library preparation and sequencing. These technical variability 
needs to be adjusted for accurate and unbiased downstream analysis. 
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Figure 3.3: Overview of analysis pipeline of SCALE. SCALE takes as input allele-specific read 
counts at heterozygous loci and carries out three major steps: (i) an empirical Bayes method for 
gene classification, (ii) a Poisson-Beta hierarchical model to estimate allele-specific 
transcriptional kinetics with adjustment of technical variability and cell size, (iii) a hypothesis 
testing framework to test the two alleles of a gene have differential bursting kinetics and/or non-
independent firing. 
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Figure 3.4: Cell size and cell cycle affects transcriptional bursting. Large cell size leads to 
large burst size due to trans-effect whereas cells with duplicated DNAs in G2 phase have 
decreased burst frequency due to cis-effect. Spike-ins are added as internal controls. Plot is 
partially adapted from Padovan-Merhar et al. (128). 
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Figure 3.5: Modeling of technical variability and parameter estimation. Amplification and 
sequencing bias are modeled and captured by parameter 𝛼 and 𝛽. Estimation is carried out by 
log-linear regression. Probability of dropout is modeled by 𝜅 and 𝜏 and depends on the logarithm 
of the true expression. Estimation is carried out by the Nelder-Mead simplex algorithm. (A) 
Estimation results from 8 spike-ins from mouse blastocyst cells (93). The percentage of zero read 
counts are decomposed into those from Poisson sampling and those from dropout (spike-ins are 
non-bursty). (B) Estimation results from 92 ERCC spike-ins from human fibroblast cells (108). 
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Figure 3.6: Gene categorization results on scRNA-seq dataset of mouse blastocyst and 
human fibroblast cells. For each gene, the proportion of cells expressing neither, one, or both 
alleles, estimated through the Bayes procedure are denoted as 𝑝0, 𝑝1, and 𝑝2. The smoothed 
scatterplot of 𝑝2 against 𝑝0 across all genes is shown. If the two alleles of a gene are expressed 
in a coordinated fashion, then there is no monoallelic expression and thus 𝑝0 + 𝑝2 = 1, which 
corresponds to the diagonal line. If the two alleles fire independently and share the same bursting 
kinetics, let 𝑝 = 𝑝𝐴 = 𝑝𝐵 be the proportion of cells expressing each allele, then we have 𝑝0 =
(1 − 𝑝)2, 𝑝1 = 2𝑝(1 − 𝑝), and 𝑝2 = 𝑝
2. This corresponds to the red curve, where 𝑝2 = (√𝑝0 − 1)
2
. 
The observed data, on the genome-wide scale, generally don’t show significant deviations from 
this red curve, providing visual evidence that for most genes the assumption of shared bursting 
kinetics and independent bursting between the two alleles is reasonable. Smooth scatterplot is 
plotted by smoothScatter function in R. For genes that are significantly deviated, hypothesis 
testing is carried out to determine whether it is due to differential bursting kinetics and/or non-
independent bursting between the two alleles. (A) Results from mouse blastocyst cells. (B) 
Results from human fibroblast cells. 
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Figure 3.7: Allele-specific transcriptional kinetics of 7486 genes from 122 mouse blastocyst 
cells. (A) Burst frequency of the two alleles has a correlation of 0.852. 425 genes show 
significant allelic difference in burst frequency after FDR control. (B) Burst size of the two alleles 
has a correlation of 0.746. Two genes show significant allelic difference in burst size. X-
chromosome genes as positive controls show significant higher burst frequencies of the maternal 
alleles than those of the paternal alleles. The 𝑝-values for allelic burst size difference (bottom 
right panels) are uniformly distributed as expected under the null, whereas those for allelic burst 
frequency difference (bottom left panels) have a spike below significance level after FDR control. 
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Figure 3.8: Examples of significant genes from hypothesis testing. (A) The two alleles of the 
gene have significantly differential burst frequency from the bootstrap-based testing. (B) The two 
alleles of the gene have significantly differential burst size and burst frequency. (C) The two 
alleles of the gene fire non-independently from the chi-square test of independence. 
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Figure 3.9: Allele-specific kinetic parameter estimation using bursty X-chromosome genes 
as positive controls. When the sample pool is mixed with male (XAY) and female (XAXB) cells, 
the maternal A allele has significantly higher burst frequency than the paternal B allele while the 
burst size difference remains insignificant. When the sample pool consists of male (XAY) cells 
only, the bursty X-chromosome genes are categorized as maternal monoallelic A expression, 
whose allelic kinetic parameters for the paternal B allele are not estimable. X-chromosome genes 
serve as a positive control and a sanity check, which shows that SCALE estimates the allele-
specific kinetics as is expected. 
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Figure 3.10: Testing of bursting kinetics by scRNA-seq and testing mean difference by 
bulk-tissue sequencing. (A) Venn diagram of genes that are significant from testing of shared 
burst frequency and allelic imbalance. *Also includes the two genes that are significant from 
testing of shared burst size. Change in burst frequency and burst size in the same direction leads 
to higher detection power of allelic imbalance; change in different direction leads to allelic 
imbalance testing being underpowered. (B) Gene Dhrs7 whose two alleles have bursting kinetics 
in different direction and gene Gprc5a whose two alleles have bursting kinetics in the same 
direction. Dhrs7 is significant from testing of differential allelic bursting kinetics; Gprc5a is 
significant from the testing of mean difference between the two alleles.  
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Figure 3.11: Allele-specific transcriptional kinetics of 2277 genes from 104 human 
fibroblast cells. (A) Burst frequency of the two alleles has a correlation of 0.859. 26 genes show 
significant allelic difference in burst frequency after FDR. (B) Burst size of the two alleles has a 
correlation of 0.692. One gene has significant allelic difference in burst size. The results are 
concordant with the findings from the mouse embryonic development study. 
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Figure 3.12: Three classes of Poisson-Beta transcription model. Each dot corresponds to a 
cell, whose read count is generated in silico with underlying true parameters shown in each 
panel. (A) Genes with small 𝑘𝑜𝑛 and small 𝑘𝑜𝑓𝑓 are bursty, whose bursting kinetic parameters are 
identifiable. (B) Genes with large 𝑘𝑜𝑛 and small 𝑘𝑜𝑓𝑓 are typically highly expressed – the system 
collapses down to a constitutive expression model, resulting in a Poisson or negative-Binomial-
like distribution. (C) Genes with small 𝑘𝑜𝑛 and large 𝑘𝑜𝑓𝑓 have low expression in most cells and 
high expression in a small number of cells, shown as a long exponential tail. (D) Genes with large 
𝑘𝑜𝑛 and large 𝑘𝑜𝑓𝑓 are statistically hard to be distinguished from genes shown in (B). 
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Figure 3.13: Assessment of moment estimators by simulations studies. Estimation accuracy 
is measured by relative estimation error |?̂? − 𝜃| 𝜃⁄  for 𝑘𝑜𝑛, 𝑘𝑜𝑓𝑓, 𝑠, and 𝑠 𝑘𝑜𝑓𝑓⁄ . Simulation is 
carried out with different underlying true parameters across 100 and 1000 cells: (A) varied 𝑘𝑜𝑛 
with fixed 𝑠 and 𝑘𝑜𝑓𝑓 acorss 100 cells; (B) varied 𝑘𝑜𝑓𝑓 with fixed 𝑠 and 𝑘𝑜𝑛 across 100 cells; (C) 
varied 𝑠 with fixed 𝑘𝑜𝑛 and 𝑘𝑜𝑓𝑓 across 100 cells; (D) varied 𝑘𝑜𝑛 with fixed 𝑠 and 𝑘𝑜𝑓𝑓 acorss 1000 
cells; (E) varied 𝑘𝑜𝑓𝑓 with fixed 𝑠 and 𝑘𝑜𝑛 across 1000 cells; (F) varied 𝑠 with fixed 𝑘𝑜𝑛 and 𝑘𝑜𝑓𝑓 
across 1000 cells. Cases where 𝑘𝑜𝑛 ≪ 𝑘𝑜𝑓𝑓 (silence) and 𝑘𝑜𝑛 ≫ 𝑘𝑜𝑓𝑓 (constitutive expression), 
shown as red and black curves, have high estimation errors. 𝑘𝑜𝑓𝑓 has higher estimation 
uncertainty than 𝑠 in burst size. 
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Figure 3.14: Correlation between allele-specific burst size 𝒔/𝒌𝒐𝒇𝒇, transcription rate 𝒔, and 
deactivation rate 𝒌𝒐𝒇𝒇. Over/under estimation of 𝑠 is compensated by over/under estimation of 
𝑘𝑜𝑓𝑓, resulting in the ratio burst size (𝑠/𝑘𝑜𝑓𝑓) having higher correlation between the two alleles. 
Each point is a biallelic bursty gene, whose kinetic parameters are estimated from real dataset of 
(A) 122 mouse blastocyst cells (93) and (B) 104 human fibroblast cells (108). 
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Figure 3.15: Power analysis for hypothesis testing of differential burst frequency and burst 
size between the two alleles. The null hypothesis is both alleles sharing the same bursting 
kinetics (𝑘𝑜𝑛
𝐴 = 𝑘𝑜𝑛
𝐵 = 0.2, 𝑘𝑜𝑓𝑓
𝐴 = 𝑘𝑜𝑓𝑓
𝐵 = 0.2, 𝑠𝐴 = 𝑠𝐵 = 50). Different alternative hypotheses are 
included in the figure legends: (A) differential burst frequency; (B) differential burst size due to 
change in 𝑠; and (C) differential burst size due to change in 𝑘𝑜𝑓𝑓. Overall, the testing of burst 
frequency and burst size have similar power with relatively low power if the allelic difference in 
burst size is due to difference in the deactivation rate 𝑘𝑜𝑓𝑓. Power is evaluated at 0.05 
significance level, suggesting a reduced power if a more stringent 𝑝-value cutoff is adopted. 
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Figure 3.16: Adjustment of cell size and technical variability leads to more accurate 
estimation of allelic bursting kinetics. Relative estimation error of burst frequency and burst 
size are measured through 5000 simulations across 100 and 400 cells respectively with fixed 
underlying true allele-specific kinetics (𝑘𝑜𝑛
𝐴 = 𝑘𝑜𝑛
𝐵 = 𝑘𝑜𝑓𝑓
𝐴 = 𝑘𝑜𝑓𝑓
𝐵 = 0.2, 𝑠𝐴 = 𝑠𝐵 = 100). Technical 
variability is simulated with the estimated parameters from the mouse blastocyst dataset (Figure 
S5A). Cell size is simulated from a normal distribution with mean 1 and standard deviation 0.1 
and 0.01 respectively. SCALE is applied in its default setting, without accounting for cell size, 
without adjustment of technical variability, and not in an allele-specific manner (using total 
coverage as input). SCALE in its default setting has the smallest relative estimation error across 
all four parallel runs. The estimation accuracy improves as the number of cells increases. 
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Figure 3.17: Adjustment of cell size and technical variability leads to more accurate 
estimation of allelic bursting kinetics. Relative estimation error of burst frequency and burst 
size are measured through 5000 simulations across 100 and 400 cells respectively with fixed 
underlying true allele-specific kinetics (𝑘𝑜𝑛
𝐴 = 𝑘𝑜𝑛
𝐵 = 𝑘𝑜𝑓𝑓
𝐴 = 𝑘𝑜𝑓𝑓
𝐵 = 0.2, 𝑠𝐴 = 𝑠𝐵 = 100). Technical 
variability is simulated with the estimated parameters from the human fibroblast dataset (Figure 
S5B). Cell size is simulated from a normal distribution with mean 1 and standard deviation 0.1 
and 0.01 respectively. SCALE is applied in its default setting, without accounting for cell size, 
without adjustment of technical variability, and not in an allele-specific manner (using total 
coverage as input). SCALE in its default setting has the smallest relative estimation error across 
all four parallel runs. The estimation accuracy improves as the number of cells increases. 
Logarithm of the estimation error is shown as the Y-axis due to the completely-off estimation 
using total instead of allele-specific expression. 
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Figure 3.18: Histogram repiling method for kinetic parameter estimation with adjustment of 
technical variability. Histogram of number of cells with observed read counts 𝑄 is shown in light 
blue; histogram of number of cells with true number of molecules 𝑌 is shown in light red. Three 
example genes are plotted: (A) Partial cells with zero read counts of a bursty gene are due to 
dropout events and are recovered to non-zero true number of molecules; (B) Gene is off in most 
cells; (C) Gene is constitutively expressed with expression levels adjusted for sequencing and 
amplification bias. 
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Table 3.1: Standard errors and confidence intervals of estimated kinetic parameters.  
Simulated dataset are generated from the Poisson-Beta transcriptional model with true underlying 
parameters shown in first row. Bootstrap resampling gives standard errors and confidence 
intervals of the moment estimates. Standard errors are large with unstable moment estimates for 
genes with 𝑘𝑜𝑛 ≪ 𝑘𝑜𝑓𝑓 (silence) and 𝑘𝑜𝑛 ≫ 𝑘𝑜𝑓𝑓 (constitutive expression). 
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